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ABSTRACT

TARGETING THE MEK5, MEK1/2, AND/OR PI3K PATHWAYS TO REVERSE
EPITHELIAL TO MESENCHYMAL TRANSITION AND ENHANCE
CHEMOTHERAPEUTIC SENSITIVITY IN BREAST AND BRAIN CANCERS

By
Akshita B. Bhatt
May 2021

Dissertation supervised by Dr. Jane E. Cavanaugh
Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer and
accounts for 10-15% of breast cancer cases. Due to absence of estrogen, progesterone, and
human epidermal growth factor receptors, there is lack of targeted therapies and chemotherapy
remains the mainstay treatment. Moreover, drug resistance is a major problem associated
specifically with TNBC. Similarly, while estrogen receptor positive (ER+) breast cancer can be
treated with targeted therapies such as tamoxifen, 40% of patients develop resistance and
resulting in recurrence of the disease.

There is a dire need for identifying novel targets and developing therapeutics to target
triple-negative and tamoxifen-resistant (TAMR) breast cancers. Activation of one of the newest
members of mitogen-activated protein kinase (MAPK) family, extracellular-regulated kinase
iv

(ERK) 5 is known to increase cell viability, proliferation, and migration in different cancers and
its overexpression correlates with poor patient survival. In breast cancer, activation of mitogen
activated protein kinase kinase (MEK) 5, the upstream kinase of ERK5, and/or ERK5 promotes
drug resistance, the epithelial to mesenchymal transition (EMT), and hormone independence.
Once the cancer cells undergo an EMT, they are harder to target and contain, leading to
metastases. Therefore, there is an urgent need to understand the pathways that drive proliferation
and the EMT and develop novel therapies that target these pathways.

TNBCs are heterogeneous in their mutational profile and reliance on specific signaling
pathways. Therefore, in addition to the ERK5 pathway, the ERK1/2 and phosphoinositol-3kinase (PI3K)-AKT pathways have been shown to have overlapping and distinct functions as the
ERK5 pathway to regulate tumorigenesis in TNBC and TAMR breast cancers. Interestingly,
inhibition of one of these signaling pathways often leads to a compensatory increased activation
of the other signaling cascades, including the PI3K-AKT pathway. Emerging evidence suggests
that the MAPK and PI3K pathways play an important role in the progression and metastases of
other aggressive cancers such as glioblastoma multiforme.

The main goals of this project are 1) to target the ERK1/2 and ERK5 pathways and
develop strategies to reverse the EMT using novel and known pharmacological inhibitors and
molecular tools and 2) determine the effect of novel and known kinase inhibitors on
chemotherapeutic sensitivity and 3) determine the effect of novel compounds that target the
ERK1/2 and ERK5 pathways in combination with the AKT inhibitor ipatasertib on spheroid
viability, migration, and proliferation in TNBCs. The results from this study will aid in the
v

design of innovative therapeutic strategies that target cancer metastases and reduce therapeutic
resistance.
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Chapter 1: Literature Review
1.1 Introduction
1.1 .1 Breast Cancer
Cancer is the second leading cause of death in the United States with 1.8 million
new cancer cases and 0.6 million deaths estimated for 2020.1 Among these cases are 0.28 million
new breast cancer cases with 42,000 anticipated deaths anticipated for the year 2020.

Metastases accounts for 90% of deaths due to cancer. Cancers display phenotypes 2-3
of increased self-sufficiency in growth signaling, an insensitivity to anti-growth signals,
increased tissue invasion and metastasis, limitless replication potential, sustained
angiogenesis, and evasion of apoptotic cell death. Breast cancer accounts for 30% of all
cancers occurring in women and triple-negative breast cancer (TNBC), which constitutes
about 10-15% of total breast cancer cases is among the most difficult to treat forms of
cancer.

1

Figure 1.1: Metastatic breast cancer. Metastatic breast cancer is challenging to treat
due to its aggressive nature and lack of well-defined therapeutic targets (Image source:
https://www.cancersupportcommunity.org/metastatic-breast-cancer). Courtesy of Bob
Morreale.
The normal mammary lobule consists of aggregate of acini embedded in the
surrounding stroma. The acini drain into a terminal ductule and a few lobules and ductules
drain together to form terminal duct lobular unit. The inner lining of the ducts and lobules
comprises of an inner epithelial layer, which stains positive for the transmembrane
adhesion molecule E-cadherin encoded by the CDH1 gene. Growth and differentiation of
normal breast tissue is regulated by estrogen and progesterone via estrogen and
progesterone receptors, respectively.
Breast carcinomas are comprised of transformed epithelial cells. Breast cancers
progress from regions of cellular atypia into clinically evident premalignant or malignant
lesions with further progression to metastatic spread and therapeutic resistance. 4 Breast
2

cancer is very heterogeneous in terms of histology, response to therapy, metastatic
patterns, and patient outcomes. Breast cancers can be classified based on the different
molecular subtypes, stage of disease, and grade (Figure 1.2). Global gene expression
analyses and high-throughput sequencing have helped characterize breast cancer as
Luminal A, Luminal B, HER2-enriched, claudin-low, and basal-like.

Figure 1.2: Histologic and molecular subtypes of breast cancer. Breast cancer can
be classified based on the origin, stage, and molecular subtypes (Image source:
http://www.pathophys.org/breast-cancer/). Courtesy of Eric Wong and Sultan Chaudhry.

3

1.1.2 Triple-negative breast cancer
TNBCs lack HER2, ER, and PR receptor expression, yet retain the growth normally
expected from activation of these receptors. It has been proposed that the pathways
display increased activity decoupled from receptor occupancy. Most TNBCs and drugresistant cancers adapt to develop a mesenchymal phenotype over time. Epithelial to
mesenchymal transition is the first step of metastases, which accounts for ~90% of
cancer-associated deaths in humans. EMT is a cascade of cellular events including the
loss of epithelial marker E-cadherin and gain of mesenchymal markers ZEB1, snail, and
vimentin. Loss of E-cadherin expression is a crucial event in the metastases and
recurrence of aggressive lobular breast cancer.5-6

1.1.3 Epithelial to mesenchymal transition and cancer metastases
The epithelial to mesenchymal transition (EMT), one of the first steps in cancer
metastases, is a continuum of morphologic transitions from cobblestone-like epithelial
state to a spindle-like mesenchymal state (Figure 1.3). The complex process of
metastases involves EMT, intravasation in the blood vessels, survival in blood stream,
extravasation at the secondary site, mesenchymal to epithelial transition (MET), and
secondary tumor growth.7 Cells can also exist in an epithelial/mesenchymal stage, where
they co-express epithelial and mesenchymal markers. This intermediate EMT state is
often associated with greater metastatic potential and poor patient outcome. Cancer
metastases requires high cellular plasticity and adaptability to survive in diverse
physiological environments. It is important to identify therapies to target different stages
4

of metastases. Upregulation of EMT transcription factors via growth factors, epigenetic
plasticity, and downregulation of tumor suppressor microRNAs (miRs) are a few
mechanisms that drive EMT in cancer.8

Figure 1.3: Events involved in epithelial to mesenchymal transition.9

Tumor heterogeneity in terms of difference in driver mutations within the same
cancer subtype and complexity of the tumor microenvironment have made the application
of oncology therapeutics extremely challenging. The extracellular signaling factors and
epigenetic effectors cooperate to initiate the EMT program and ultimately lead to
metastases. One of the cellular adaptations during EMT involves increased capabilities
of cancer cells to preferentially interact with the extracellular matrix, rather than the
adjacent epithelial and stromal cells. Integrins are known to activate Src and focal
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adhesion kinases (FAK), which results in an increase in secretion of matrix
metalloproteinases, loss of E-cadherin, and disruption of the adherens junctions (AJs).10
Tumor-associated chronic inflammation could initiate EMT via crosstalk between
the inflammatory and tumor cells.11 The tumor is infiltrated by diverse inflammatory and
immune mediators. For example, 50% of the tumor is infiltrated with inflammatory
macrophages. These infiltrated activated macrophages and proinflammatory T-cells can
release cytokines, including transforming growth factor-β (TGF- β), tumor necrosis factor
α (TNF- α), and interleukin-6, which are potent EMT inducers.12 Expression of immune
checkpoint proteins such as PD-L1 mediates escape of cancer cells from NK cellmediated cytotoxicity. In the given feedforward mechanism, EMT increases in PD-L1
expression via the microRNA-200-ZEB1 axis, which results in immune suppression and
metastases.13 Several mechanisms that regulate EMT are summarized in Figure 1.4.

Figure 1.4: Mechanisms that drive EMT in cancer. EMT in gradual progression from a
cobblestone-like morphology to spindle-like morphology, initiated by growth factors,
activation of MAPK pathway, and upregulation of transcription factors involved in EMT.
Original figure created in Biorender.com.
6

Another feature that the cancer cells adopt as they transition to a mesenchymal
state and enter the blood circulation for metastases is their ability to activate and bind
platelets. At this stage, the cancer cells are termed as circulating tumor cells. Many
studies argue that the cells are in an intermediate epithelio-mesenchymal state at this
stage. There are coagulation-dependent mechanisms modulated via fibrin, which help the
cancer cells to bind platelets and gain protection against loss of anchorage-triggering
anoikis, immune attack, and shear stress.14 Drug resistant stem cells at the primary and
metastatic sites are also known to possess EMT characteristics.15
1.1.4 The Mitogen-Activated Protein Kinase Pathway in cancer
MAPK pathway is activated in response to growth factors, cytokines, stress, and
hormones and leads to alteration of cell division, proliferation, and differentiation.
Mutations in BRAF, KRAS, EGFR, and receptor tyrosine kinase (RTK) pathways can lead
to constitutive activation of MAPK pathway, characterized by phosphorylation of
downstream targets MAPK/ERK Kinase Kinase 2 (MEKK2)/3, ERK1/2, ERK5, RSK, and
FRA-1. Figure 1.5 summarizes the intracellular signaling pathways, which are involved in
cell viability, proliferation, epithelial to mesenchymal transition, and migration.

7

Figure 1.5: Pathways driving ERK activation and cellular process regulated by the
kinase.16
Activation of MAPK can increase EMT, migration, invasion, and stemness in
several cancers. Extracellular-regulated kinase (ERK)1/2 is one of the most wellcharacterized members of the MAPK pathway. ERK1/2 activation can be a result of
tyrosine kinase dimerization, RAS, or RAF mutation. RTKs serve as binding sites for the
Src homology and collagen (SHC) adapter protein and growth factor receptor-bound
protein (GRB2). These adapter proteins have phosphotyrosine-binding (PTB) and SH2
8

domains. GRB2 then interacts with Son of Sevenless (SOS) through its SH3 domain,
leading to the activation of MEK1/2 and MEK5.
1.1.4.1

ERK1/2 pathway in cancer

Extracellular signal-regulated kinase (ERK)1 and ERK2 isoforms share 85%
sequence homology and can be activated by phosphorylation at the TEY motif (Thr202
and Tyr204).17 The ERK1/2 pathway is one of the most well characterized MAPK
pathways in cancer (Figure 1.6). The MAPK cascade and subsequent ERK1/2 is initiated
when an extracellular signal activates the corresponding receptor and causes
conformational changes and activation of the small GTPase RAS at the plasma
membrane. RAS activates Raf-MEK-ERK by phosphorylation of serine residues. This
pathway is activated in 85% of all cancers due to mutations in RAS, RAF, MEK or
epidermal growth factor receptor (EGFR). ERK1/2 activation leads to subsequent
activation of downstream effectors and gene transcription. These signals are amplified at
each stage. ERK1/2 is known to induce fos and jun, Activator protein 1 (AP-1),
Erythroblast Transformation Specific ETS-1 genes. Moreover, ETS-1 has been found to
upregulate ZEB1 expression and regulate EMT in breast cancer. 18
Connexin 43 (inhibitor of gap junction communication) and regulator of cell
migration myosin light chain kinase (MCLK) are plasma membrane proteins activated by
ERK1/2.19 ERK1/2 activation leads to association of paxillin to Src. 20 Ribosomal S6 kinase
(RSK), mitogen and stress-activated protein kinase (MSK), and MAPK-interacting kinase
(MNK) are the main cytoplasmic substrates of ERK.21 RSK family are known to be
exclusively activated by ERK1/2 but we have found that ERK5 can also modulate RSK
activity. The activity of transcription factors cAMP response element binding (CREB),
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serum response factor (SRF), estrogen receptor (ER) is modulated by RSK activation.
RSK also regulates pro-apoptotic protein Bcl-2-associated death promoter (BAD). Direct
and indirect regulators of ERK1/2 signaling cascade and downstream effectors are
summarized in figure 1.5. While ERK1/2 pathway in cancer is well-understood, the details
about ERK5 pathway in cancer are only being recently explored.
RAS is an important regulator of ERK1/2 pathway. RAS mutation can promote
cancer growth via influencing several hallmarks of cancer described by Weinberg et. al.:
Sustained growth and proliferation, evasion of immune system, invasion, inhibition of
apoptotic signaling, EMT, and alteration of cell metabolism. Reasons why RAS is
undruggable include: (i) binding of RAS to GTP (covalent interaction) results in the closing
of GTP-binding domain on RAS, thus making the binding pocket inaccessible for RAS
inhibitors. (ii) Unique C-terminal domain: C-terminal domain of RAS can undergo posttranslational

modifications,

including

palmitoylation

and

farnesylation.

Several

approaches were developed to target these post-translational modifications. However,
RAS mutant cancer cells adapted to develop an alternative PTM mechanism known as
GGTase (geranylgeranyl isoprenoid), preventing RAS from turning off. Therefore,
targeting the downstream effector of RAS signaling including the MEK1/2-ERK1/2 and
MEK5-ERK5 signaling pathways is a relevant strategy to target RAS-mutant cancers.
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Figure 1.6: Upstream and downstream regulators of the ERK1/2 pathway22
1.1.4.2 ERK5 pathway in cancer
ERK5, the newest member of the mitogen-activated protein kinase family (MAPK),
is a marker for poor prognosis in cancer patients.23 ERK5 is one of the members of the 4
MAPK signaling cascades, including ERK1 and ERK2, c-JUN N-terminal kinase (JNK) 1,
and p38-MAPK. These cascades are regulated by 3 to 5 tiers of phosphorylation events,
which are initiated by receptor tyrosine kinases and subsequent components of the MAPK
family. While these pathways are under strict regulation by feedforward activation and
feedback inhibition loops in healthy cells, these do not operate similarly in cancer cells.
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Although ERK1/2 and ERK5 pathways share greater than 50% sequence
homology at the N-terminal domain, ERK1/2 and ERK5 have been shown to mediate
differential responses to growth factors, hypoxia, and pharmacological targeting with
BRAF and MEK1/2 inhibitors. ERK1/2 and ERK5 pathways regulate hypoxia-related
genes via distinct mechanisms in normoxic versus hypoxic condition.24 These differences
could be attributed to the unique C-terminal domain of ERK5, which contains two prolinerich regions and a nuclear localization sequence and facilitates transcriptional activation
of oncogenes.25 We have most recently studied the overlapping and distinct functions of
ERK1/2 and ERK5 signaling in regulating EMT in triple negative and tamoxifen-resistant
breast cancer.26
High ERK5 expression correlated with EMT, drug resistance, and poor patient
survival in several cancers.27-30 Whole-genome microarray analysis revealed that
overexpression of cyclin-dependent kinase 5 (CDK5), an important prognostic marker for
development of malignant CRC in human samples, could directly activate ERK5 and
promote progression of colorectal cancer via AP-1.31 ERK5 negatively correlated with
miR-143

expression

and

regulated

proliferation,

migration,

and

invasion

in

osteosarcoma.32-33 DNA damage initiates apoptotic signaling cascade via activation of
ataxia-telangiectasia mutated (ATM) kinase, which is a cell cycle regulator and mediates
phosphorylation of DNA damage and repair marker H2AX. Loss-of-function mutation in
ATM is one of the causes of cancer and ERK5 deletion in ATM-/- mice has been shown
to delay tumorigenesis and increase response to DNA-targeting agents via H2AX
phosphorylation in thymic lymphoma.34 This was one of the few studies to identify the role
of ERK5 in relation to tumor suppressors.
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1.1.4.3 Mechanisms for dysregulated ERK5 signaling in cancer
Activating mutations in genes such as BRAF (70% melanoma, 59% thyroid, 10%
colon, and 6.7% lung cancer)35 and KRAS (90% pancreatic, 50% thyroid, 30% lung, 15%
ovarian, breast, liver, kidney cancer, and leukemias) have a major influence on MAPK
signaling in several cancers. Most of these cancers have FDA-approved therapies as a
line of treatment, but it becomes really challenging to treat these cancers once they
metastasize. BRAF mutations in particular are known to mediate the EMT and
metastases via hyperactivation of the MAPK, nuclear factor kappa B (NF-kB), and
phosphatidyl inositol-3-kinase (PI3K)/AKT pathways.36
ERK5 and AKT pathways are known to transactivate each other and regulate cell
survival via phosphorylation and cytosolic sequestration of the pro-apoptotic protein Bad
in triple negative breast cancer (TNBC).37 Moreover, PI3K/AKT pathway is also known to
mediate MEK5-ERK5 activation in malignant mesothelioma and neuroblastoma.38-39
Hepatocyte growth factor (HGF) and its receptor c-met are also known to activate ERK5
and upregulate one of the downstream targets fos-related antigen-1 (FRA-1) via PI3KAKT signaling in malignant mesotheliomas (MMs). 38 HGF also induced ERK5 and protein
tyrosine kinase (PTK) 6 activation and cell migration in breast cancer cells.40 Plateletderived growth factor (PDGF) BB increased bone morphogenetic protein (BMP) signaling
in fibroblasts via PI3K-MEK1/2-MEK5-ERK5 activation.41 Interleukin-6 is known to
promote ERK5 activation and proliferation in multiple myeloma.42
Hyperactivation of ERK5 could be a result of downregulation of tumor suppressor
proteins, microRNAs, or phosphatases/ proteases that inhibit ERK5 via a negative
feedback loop. microRNAs (miRs) are a class of short non-protein-coding single-stranded
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RNAs and their function is to silence protein expression post-transcriptionally. These bind
with the 3’-untranslated region (UTR) of the target mRNAs, leading to their translational
repression or destabilization. Loss of tumor suppressor miRs is an important mechanism
responsible for the overexpression of oncoproteins. Some studies suggest that ERK5 is
negatively regulated by tumor suppressor miRNAs miR-143 and miR-200 in breast cancer
and glioblastoma, respectively.43-44
Downregulation of transcription factor special AT-rich sequence-binding protein 2
(SATB2) via miR-31, miR-34, or TGF-b signaling has been indicated to be associated
with cancer progression.45 High SATB2 expression correlates with favorable prognosis
and enhanced chemosensitivity in colorectal cancer (CRC).45-46 Overexpression of
SATB2 increased the epithelial marker E-cadherin, decreased mesenchymal markers
vimentin, N-cadherin in CRC cell lines in vitro, and suppressed metastases in vivo.47
SATB2 was identified to inhibit ERK5 activity and decrease CRC cell migration, invasion,
and colony formation in vitro and tumor progression in vivo.48 However, the total ERK5
expression was unaffected, indicating that SATB2 may not transcriptionally regulate
ERK5. Finally, ERK5 degradation is mediated by the tumor suppressor von Hippel-Lindau
(VHL)

through

prolyl

hydroxylation-dependent

ubiquitination

and

subsequent

proteasomal degradation.49 VHL gene is often mutated in clear cell renal cell carcinoma
(CCRCC). Hypoxia-inducible factor-1α (HIF-1α), one of the major targets of VHLmediated degradation, mediates the survival of cancer cells under low oxygen
conditions.50 Disease-specific survival was greater with high ERK5 and HIF-1α
expression and low VHL expression in CCRCC patients, indicating ERK5 as an essential
target in CCRCC. Molecular mechanisms regulating ERK5 are summarized in figure 1.7.
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Figure 1.7: Upstream and downstream regulators of EMT mediated via ERK5.
Original figure created in Biorender.com.
1.1.4.4 Crosstalk between the ERK1/2 and ERK5 pathways
Crosstalk among the different members of the MAPK family, including ERK1/2 and
ERK5, has been noted. ERK1/2 and ERK5 are known to commonly regulate downstream
targets such as RSK, c-Fos, and CD-1. We have shown that novel inhibitors of MEK1/2
and MEK5 pathways reverse the mesenchymal phenotype of MDA-MB-231 TNBC cells
to epithelial and increase E-cadherin protein expression.51 Some studies revealed that
targeting the ERK1/2 pathway can lead to a compensatory increase in ERK5 activation
via upregulation of c-MYC or IGFR.52-55 ERK5 can compensate for targeting ERK1/2 to
inhibit upregulation of macrophage colony stimulating factor receptor (M-CSFR)15

mediated macrophage differentiation in acute myeloid leukemia cells. 56 Inhibition of both
ERK1/2 and ERK5 has been found to be necessary for efficient targeting of NRAS and
BRAF-mutant melanomas.52,

54-55, 57

On the contrary, ERK5 has been found to be

downstream of the BRAF-MEK1/2-ERK1/2 signaling in melanoma and ERK1/2 is known
to promote nuclear localization of ERK5 in HEK293 and PC12 cells via Thr732
phosphorylation (Figure 1.8).58-59 Although the MEK1/2-ERK1/2 pathway is fairly
understood in regulating EMT in cancer, the involvement of the MEK5-ERK5 pathway in
EMT is overlooked (293 versus 22 results in Pubmed search). ERK1/2 and ERK5 were
thought to have redundant roles, our research goals include examining distinct and
overlapping roles of ERK1/2 and ERK5 pathways on MET in breast cancer. Roles of
ERK1/2 and ERK5 pathways in regulating EMT are discussed in more detail in chapter
four.

Figure 1.8: Putative crosstalk between the ERK1/2 and ERK5 pathways. 60
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1.1.5 PI3K/AKT pathway in cancer
The crosstalk between MAPK and PI3K pathways has been noted in cancer.61 In
our study, we propose dual inhibitors of MEK5 and PI3K pathways as a strategy to target
cancer. Therefore, this section includes the details on the PI3K/AKT signaling pathway.
The PI3K/AKT signaling pathway is involved in proliferation, cell survival, apoptosis,
differentiation, vacuolar trafficking, and cytoskeletal rearrangement. Class I PI3K family
of proteins are implicated in cancer, which is activated by receptor tyrosine kinase, Gprotein coupled receptor, and various oncoproteins. The 110-kDa catalytic subunit (p110)
of PI3K is associated with an 85-kDa adapter, non-catalytic subunit (p85). p85 subunit is
encoded by various genes that code for multiple proteins with distinct function, most of
the splice variants, and adapter subunits two Src-homology 2 (SH2) domains. A p110binding domain is located between the two SH2 domains, which allows for the interaction
and stabilization of p110 protein and inhibition of the PI3K kinase activity.62
Phosphorylation of tyrosine at the growth factor receptor recruits p85 to the cell
membrane, relieving its inhibition on p110. Subsequently, PI3K colocalizes with its
regulatory molecules and substrate membrane phosphatidylinositols.63 The PI3K-AKT
pathway is illustrated in figure 1.9.
PI3K complex is recruited from the cytoplasm to the inner cell membrane when
growth factor binds to the receptor tyrosine kinases. PI3K phosphorylates and converts
its substrate phosphatidylinositol (4,5) bisphosphate (PIP2) at the 3-position of the inositol
ring to form the secondary messenger phosphatidylinositol (3,4,5) triphosphate (PIP3).
The reverse conversion is regulated by the action of the phosphatase and tensin homolog
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(PTEN). The levels of PIP3 are controlled by SH2-containing inositol-5-phosphatase
(SHIP).64 PIP3 is an anchor for proteins such as AKT1, AKT2 and AKT3, which contain
Pleckstrin Homology (PH) domain. These proteins are activated by 3-phosphoinositide
dependent protein kinase-1 (PDK1) when localized to the membrane; further activation
of downstream targets such as mTOR, Bad, Caspase 9, GSK3B, tuberin, and certain
forkhead transcription factors is initiated.65-67
The major targets of the PI3K/AKT pathway include PI3Ks, PDK1, AKT, and
mTOR. The most common research tools used to inhibit this pathway include LY294002
and wortmannin, which target the catalytic site of p110. LY294002 did not pass clinical
trials because of its unfavorable pharmacokinetic profile and toxicity. New inhibitors of the
class imidazopyridines, quinazolyne, pyridopyrimidines, thiazoles that target the catalytic
ATP-binding pocket are in development.68
1.1.5.1 p110: the catalytic subunit:
The catalytic class I PI3K isoforms of p110: p110α, p110β, p110δ, and p110γ are
known to preferentially govern cell signaling and tumor cell survival depending upon the
malignancy and the genetic or epigenetic aberrations. 69 Simultaneous mutations are
frequent in triple-negative breast cancer, endometrial, and prostate cancer. However,
many cancers respond much better to single isoform inhibition when compared to panPI3K inhibition. The two distinct functions of p110 isoforms p110a and p110b have been
recently studied, which provide a platform for targeting the pathway in the context of the
oncogenic driver of AKT signaling: PIK3CA mutation or PTEN loss. Hence, isoform
specific targeting could be a novel therapeutic targeting strategy.
18

PIK3CA mutation driven cancers are dependent on p110a signaling, however,
p110b is the major isoform known to drive tumorigenesis in PTEN deficient cancers.
PIK3CA mutant cell lines exhibit greater sensitivity to pan-PI3K inhibitors compared to
PTEN deficient cancers. Similar response has been observed in the clinic.70 This might
be the case because pan-PI3K inhibitors are more potent against p110a isoform versus
the p110b isoform.
The importance of developing isoform specific inhibitors is to target specific
mutations in the PI3K pathway and avoid cumulative toxicity of inhibiting irrelevant
targets. Most cancers characterized by PI3KCA mutation or amplification are more
sensitive to p110a inhibitors such as INK1402, which led to 80-100% growth inhibition
versus about 50% growth inhibition in the PTEN mutant cancers, which exhibited
resistance.
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Figure 1.9: The PI3K-AKT pathway in human cancer.71
1.1.5.2 Targeting specific p110 isoforms:
The development of isoform specific inhibitors helped to delineate the functional
role of p110α and p110β. The p110α knockout mice were embryonic lethal at day 9.510.5, and the embryos showed proliferative defects and impaired insulin signaling.72 The
p110a-null embryos and MEFs with kinase-dead p110 knock-in mice showed impaired
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growth and insulin signaling with homozygous and heterozygous kinase-dead p110a
knock-in, respectively, indicating a kinase dependent function of the p110a isoform.73
p110β knockout also leads to early embryonic lethality and impaired cell proliferation.
However, p110b-null MEFs reconstituted with a p110b kinase-dead allele survive
normally, suggesting a kinase independent function of the p110b isoform, and its role as
an important scaffold.74-75
A panel of breast cancer cells MCF7, BT474, BT20, and BT47D with mutant p110a
are sensitive to p110a isoform-specific inhibitors.76 Targeting p110a isoform inhibits tumor
cell proliferation, chemoresistance, and mig77ration in medulloblastoma cells that overexpress p110a. p110a inhibition is effective also in tumors that harbor mutant Ras and
PTEN deficiency, which exacerbate the oncogenic transformation. Although the rates of
activating mutations in PIK3CA gene are high, loss of PTEN is the most common
mechanism for oncogenic PI3K signaling in most cancers. It was misconstrued in the past
that frequent activation of p110a was the major oncogenic driver and the loss negative
PI3K regulation by PTEN mutation contributed to the aberrant signaling. However, p110a
ablation in PTEN mutant cancers did not significantly affect tumorigenesis.78
In contrast, p110b targeting sufficiently inhibits downstream AKT activation and
tumor formation in PTEN deficient prostate cancer.78 It is important to consider that PTEN
loss could be an amplifier of PI3K signaling coupled to an initial weak signal driven by
either PIK3CA, GPCR or p110a mutation, which has an influence on the type of response
to specific isoform inhibition. Cell lines with PTEN loss and coexisting PIK3CA or Ras
mutation were sensitive to p110a and dual p110a/mTOR inhibition, but not p110b
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inhibition.79 However, if the signals are initiated from a GPCR, then p110b inhibition would
be a more relevant strategy to reduce tumor formation.
1.2 Statement of the Problem
Reversing epithelial to mesenchymal transition (EMT) is an emerging strategy to
target the invasive cancers that show poor sensitivity to chemotherapeutic agents. EMT
is characterized by loss of cell polarity, disruption of intercellular junctions, reorganization
of the cytoskeleton, downregulation of E-cadherin, and increased cell migration and
invasion80 Disruption of actin skeleton via ras and src mediated activation of extracellular
regulated kinase 1/2 (ERK1/2) and ERK5 is reported, indicating their role in oncogenic
transformation81. Most invasive cancers, including triple negative (TNBC) and tamoxifen
resistant (TAMR) breast cancers have a mesenchymal phenotype. There are no current
studies that have explored the role of MAPK inhibitors as inducers of mesenchymal to
epithelial transition (MET), the reverse process of EMT, in breast cancer.
Activation of mitogen activated protein kinase (MAPK) pathways, including ERK1/2
and ERK5 signaling cascades can activate downstream targets such as Fos-related
antigen (Fra-1), zinc finger E-box binding protein ZEB1, and Slug, which lead to EMT 82.
Several MEK5 independent mechanisms for ERK5 activation and nuclear localization,
mediated via phosphoinositol-3-kinase (PI3K)/AKT and MEK1/2 pathways, respectively
have been reported39,

60

. A crosstalk between AKT and ERK5 pathways has been

suggested as a mode of chemoresistance in breast cancer cells. The goal of this research
is to examine the independent and converging roles of MEK1/2 and MEK5 in regulating
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EMT, crosstalk with the AKT pathway, and chemoresistance in mesenchymal breast
cancer cells.
1.2.1 Research Objectives
1.2.2 Hypothesis and Specific Aims:
Hypothesis: MEK5 and MEK1/2 or PI3K pathway inhibition will reverse epithelial to
mesenchymal transition and enhance chemotherapeutic drug sensitivity in breast and
brain cancers.
Specific Aim 1: To elucidate the structure-activity relationship of novel diphenylamine
analogs that induce mesenchymal to epithelial transition in breast cancer.
Specific Aim 2: To elucidate the effect of targeting the ERK1/2 and ERK5 pathways
using pharmacological inhibitors and molecular tools on MET in breast cancer.
Specific Aim 3: To examine the effect of ERK1/2, AKT, and ERK5 pathway inhibitors on
chemosensitivity in triple negative and tamoxifen resistant breast cancer cells.
Specific Aim 4: To examine the effect of dual ERK5 and ERK1/2 or AKT inhibition on
MET, proliferation, migration, and colony formation in glioblastoma multiforme.
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Chapter 2: Methods
2.1 Cell Culture and Reagents
MDA-MB-231, MDA-MB-231 VIM RFP, BT-549, MCF-7, and U87MG cell lines
were obtained from American Type Culture Collection (ATCC). MDA-MB-231 cells were
maintained in Dulbecco’s Modified Eagle Medium and Ham F-12 (1:1), BT-549 and MCF7 cells were maintained in RPMI- 1640 medium, and U87MG cells were cultured in MEM
medium supplemented with 5% FBS (Gibco) and 0.5% Pen Strep (Gibco) in a humified
atmosphere containing 5% CO2 at 37◦C. To generate a tamoxifen resistant cell line, MCF7 cells were cultured in phenol red-free RPMI-1640 media, supplemented with 5%
charcoal-stripped FBS in the presence of DMSO or 0.1μM (Z)-4-Hydroxytamoxifen (4OHT) (Sigma-Aldrich Cat. No. H7904) for 6 months. Charcoal-stripped FBS was used to
remove endogenously expressed protein growth factors present in the media (TAMR
MCF-7 cell line was generated by Dr. Thomas Wright).
2.2 Inhibitor treatment and EGF stimulation
To examine the specificity of the kinase inhibitors, cells (500,000 cells/well) were
cultured in a 6-well plate for 24 hours. To examine kinase activity or inhibition, the cells
were serum-starved for 18-24 hours. The inhibitors XMD8-92 (Tocris, Minneapolis, MN),
Trametinib (Selleckchem, Houston, TX), and VX-11e (Cayman chemical, Ann Arbor, MI)
were added for 30 minutes prior to EGF (100ng/ml) stimulation for 15 minutes as
described previously.83 Cell lysates were examined for kinase activation using standard
western blot procedure.
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2.3 Lentivirus treatment
Since pharmacological inhibitors may have off-target effects, molecular tools were
utilized in our study to examine the kinase pathway and EMT/ MET. Lentivirus vectors
were a generous gift from Dr. Zhengui Xia (University of Seattle, Washington). MDA-MB231, MDA-MB-231 VIM RFP, and BT-549 cells were cultured in a 12-well plate (150,000
cells/ well). The volume of lentivirus (µL) required per well was calculated as [(# of
cells/well x desired multiplicity of infection (MOI)/viral titer (IU/µL)]. This volume of
lentivirus was diluted in fresh media. 50% of media was replaced with the lentiviruscontaining media. The transfection efficiency was about 50% after 24 hours of infection
at MOI=1, as calculated by microscopic observation of the percentage of GFP-positive
cells. The cells were infected with lentivirus at the MOI =1 for 96 hours. Western blotting
was performed to examine cell E-cadherin and ZEB1 protein expression or ERK1/2 and
ERK5 activation, respectively and immunocytochemistry was performed to examine cell
morphology.
Lentivirus Vector

Titer (IU/ml)

Cryobaby color

GFP

3.35x108

Green

caMEK5

4x107

Yellow

dnMEK5

5x106

Yellow

wtERK5

107

Red
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dnERK5

3.2x107

Yellow

caMKK1

1.85x107

Orange

dnMKK1

3.10x107

Blue

Table 2.1 Lentivirus titer
2.4 Nuclear/Cytosolic fractionation
Cells were cultured in 6-well plates (500,000 cells/well) for 24 hours. After 24
hours, cells were treated with the kinase inhibitors for 72 hours. The nuclear/ cytosolic
fractionation was performed using standard manufacturer’s instructions (Cell Biolabs,
San Diego, CA). In brief, the medium was aspirated, and cells were washed with prechilled 1X PBS. DTT and Protease inhibitor cocktail was added to Cytosol Extraction
Buffer (CEB). 100 µL CEB was added to cells for 10 minutes. Cells were scraped and
collected in 1.5 mL pre-chilled microcentrifuge tubes. Cell lysis buffer was added for 5-15
minutes and the lysates were vortexed for 10 seconds. The lysates were centrifuged at
10,000 rpm for 10 minutes at 4°C. The supernatant (cytosolic fraction) was collected and
stored at -80°C. The pellet was resuspended in CEB and lysis buffer was added for 10
minutes. The suspension was vortexed and centrifuged at 10,000 rpm for 10 minutes at
4°C. The supernatant was discarded, this step was performed to ensure clean separation.
The pellet was resuspended in 40 µL nuclear extraction buffer (NEB) with DTT and
protease inhibitors. The solution was incubated on ice for 30 minutes with occasional
vortexing. The samples were centrifuged at 14,000 rpm for 30 minutes at 4°C. The
supernatant (nuclear fraction) was stored at -80 °C.
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2.5 Western Blot Analysis
Cells were lysed at experimental endpoint in 1X cell lysis buffer (Cell Signaling
Technology) and 0.1M PMSF. The proteins were resolved using 8% SDS polyacrylamide
gel electrophoresis and transferred to nitrocellulose membranes (LI-COR Biosciences;
Lincoln, NE). The membranes were blocked for 1 h at room temperature and incubated
at 4°C overnight with respective primary antibodies (Appendix B) diluted in casein
blocking buffer (LI-COR Biosciences). The membranes were washed three times with
wash buffer (PBS 1X, Tween 0.02%) at 10-minute intervals. The membranes were
incubated with goat anti-mouse (1:10000, Invitrogen) and goat anti-rabbit (1:10000,
Invitrogen) secondary antibodies for 1 h. Membranes were washed three times at 10minute intervals with PBS-tween wash buffer and scanned on an LI-COR’s Odyssey CLx
Imager at 700 nm (goat anti-rabbit) and 800 nm (goat anti-mouse). The blots were
quantified with LI-COR Image Studio Software.
2.6 Crystal Violet Staining
Crystal violet staining was performed to examine cell morphology. Cells (50,000
cells/well) were seeded in a 12-well plate for 24 hours and treated with 1μM concentration
of compounds for 5 days. After 5 days, media was aspirated, and cells were gently
washed with 1X PBS. Cells were fixed with 50 μl 4% paraformaldehyde per well for 15
minutes. Cells were washed once with 1X PBS and stained with 50 μl crystal violet per
well for 15 minutes. Cells were washed with 100 μl PBS three times and imaged using
EVOSTM FL inverted microscope (Life Technologies) under 10X magnification.
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2.7 Spindle Index Calculation
Spindle index calculation was performed to quantify cell shape and validate the
structure-activity relationship of the novel diphenylamines. Spindle indices (SI) of
individual cells were calculated from at least 200 cells per treatment from at least three
images as the ratio of length (l) to width (w); SI = l/w of each cell. Cells with SI < 3 were
considered as epithelial.84 % cells with SI<3 were calculated as the ratio of the number of
cells with spindle index < 3 to the total number of cells per image. The method was
adopted from reference 82. Length and width of cells were measured using the Image J
software, U. S. National Institutes of Health, Bethesda, Maryland, USA.

Figure 2.1: Calculating the spindle index85
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Figure 2.2: Validating spindle index calculation using panel of breast cancer cell
lines: Cells with mesenchymal phenotype correspond have SI value > 3.
2.8 Colony Formation Assay
Colony formation assay was performed to examine the growth of cells in 3-D
extracellular matrix-based conditions. Colony formation assay was performed using a Soft
Agar Colony Formation assay (Cell Biolabs; CBA-130). Briefly, base agar layer was
added first. MDA-MB-231 cells (5,000 cells/well) were cultured in 5% FBS growth media
and 1.2% agar solution in a 96-well plate. DMSO or compound 1 (0.1, 1, and 10 μM)
diluted in media was added on the top of cell layer. The colonies were allowed to grow
for 7 days. The agar layer was solubilized, the colonies were lysed and stained with
CyQuant dye. Florescence at 485 nm was measured on VICTOR3 1420 Perkin Elmer
multi-label counter.
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2.9 Spheroid Culture
Spheroid culture was performed to examine the effect on cells that have gained
the ability to survive in anchorage-independent conditions. Cells (5,000 cells/ well) were
cultured in 96-well low attachment plates (Corning Cat. No. 4520). DMSO or inhibitors
were added after 24 h of plating. Pictures were taken using the EVOSTM FL inverted
microscope (Life Technologies) under 4X magnification at the time of treatment and after
7 days from treatment. 10 μl of Reliablue viability reagent (ATCCR 30-1014TM) was
added to each well after 7 days from treatment. The plates were incubated in the incubator
at 37◦C for 3 h. The fluorescence was measured at ex570/ em590 on a Synergy
microplate reader (Biotek, Winooski, VT). Data is represented as spheroid viability
normalized to DMSO control ±SEM of triplicate experiments.
2.10 Immunofluorescence Assay
Immunofluorescence assay was performed to examine number of proliferating
cells, cell morphology, and EMT marker ZEB1 after treatment with kinase inhibitors. Cells
were plated at a density of 5,000 cells/well in a 96-well plate for 24 hours. After 72 hours
of treatment, cells were fixed with 4% paraformaldehyde for 15min and washed with 1X
PBS. Cells were blocked for 1 h with 0.3% Triton-X solution in Casein blocking buffer and
1X PBS. The Primary antibodies α-actinin, α-tubulin, and Ki67 (Cell Signaling
Technology) were added at a dilution of 1:750 and plate was incubated overnight at 4°C.
The cells were subsequently washed three times at 5-minute intervals, incubated for 1 h
with goat anti-mouse Alexa Flour 488 nm and goat anti-Rabbit Alexa Flour 555 nm
(1:1000, Invitrogen), and counterstained with Hoechst (Fisher) to visualize the nucleus.
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The cells were washed with 1X PBS three times at 5-minute intervals. The plate was
imaged with the EVOSTM FL inverted microscope (Life Technologies). The proliferative
index was calculated as the ratio of number of Ki67+ cells to the number of Hoechst+ cells.
2.11 Scratch Assay
Cell migration was assessed using a scratch assay after treatment with DMSO or
inhibitors for 72 hours. Cells were seeded at a seeding density of 50,000 cells/ well in a
12-well plate in 1ml full media in the presence of 5% FBS. Scratches were made after 48
h of the treatment (0 hr). The underside of the plate was marked to denote the location of
the initial wound. Cells were washed gently with 1x PBS to remove detached cells and
debris. Images were taken at the time of scratch and after 24 h from the time of scratch.
Cell migration was calculated as wound closure = (border width at 24 h-border width at 0
h)/ (border width at 0 h) X 100. Results are represented as cell migration normalized to
DMSO control ± SEM of experiments repeated three times. The principle behind cell
migration is illustrated in figure 2.4.

Figure 2.3 Treatment scheme for scratch assay
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Figure 2.4 Principle behind cell migration assay. Cells in the front end of the scratch
differentially express genes involved in cell motility, migration, and wound healing (figure
reproduced with permission).86
2.12 Cell Viability Assay
Cell

viability

was

evaluated

using

MTT

(3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide) assay. Cells were seeded at a density of 5,000 per well in
96-well plates containing 90 μl of full media for 24 h. Cells were then treated inhibitors for
72 hours. After 72 hours, 10 μL of MTT (Acros, Cat. No. 298-93-1) solution (5 mg/ml in
phosphate-buffered saline, PBS) was added to each well. The plate was incubated at
37°C and 5% CO2 for 3 hours. After removal of the MTT solution via aspiration, 100 μl of
DMSO was added to the wells for 10 minutes under agitation to dissolve the formazan
crystals. Absorbance was measured at a wavelength of 570 nm using Wallac 1420
software on a Perkin Elmer 1640 multilabel counter. Results are represented as cell
viability normalized to DMSO control ± SEM of triplicate experiments repeated three
times.
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2.13 Synergy Calculation
Data from combination experiments were analyzed using the CompuSyn (v1.4) synergy
software. Individual concentration response graphs of SC-1-151 in combination with JQ1 or LBH-549 were compared to 1:1 combination ratio. Combination indices (CI) < 1 and
fraction affected (Fa) > 50% were considered synergistic.
2.14 Statistical Analyses
Two-tailed Student’s unpaired t-test was used in to analyze data that involved a
comparison between treated (diphenylamine derivatives) and control (DMSO) groups
(fold change, E-cadherin and spindle index). If p-values were below 0.05, differences
were considered significant. Data represent ± SEM of at least three independent
experiments. One-way analysis of variance (ANOVA) with Bonferroni post-hoc correction
was used to examine concentration-dependent effect of the inhibitors on cell viability,
proliferation, spheroid viability, and cell migration. Two-tailed Pearson correlation analysis
and linear regression was used for correlation experiment. Statistical analyses were
performed using GraphPad Prism version 8 for Windows, GraphPad Software, La Jolla
California USA.
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Chapter 3: Novel diphenylamine analogs inhibit MEK1/2 and MEK5 pathways,
induce a mesenchymal to epithelial transition, and decrease spheroid formation,
cell migration, and proliferation in triple-negative and tamoxifen-resistant breast
cancer cells
3.1 Introduction
Triple negative breast cancers (TNBC) account for about 13-15% of total breast
cancer cases.87 TNBCs are associated with poor prognoses and patient outcomes, and
a high frequency of relapse. About 70% of breast cancer patients are diagnosed with ERpositive breast cancer. These patients can be treated with ER-antagonists, such as 4Hydroxytamoxifen (4-OHT). However, the incidence of developing tamoxifen-resistance
(TAMR) is high.88 Tamoxifen-resistance is also associated with gain of a mesenchymal
phenotype due to β-catenin phosphorylation.89 TNBCs and TAMR cancers have a
mesenchymal phenotype. Mesenchymal cells are migratory and invasive, which leads to
secondary tumor formation or metastasis. Metastasis is the leading cause of death in
cancer, and there are currently no treatments that effectively inhibit metastasis.
Therefore, there is a dire need of targeted therapy for TNBCs and TAMR cancers.
Mitogen Activated Protein Kinase (MAPK) pathways are important regulators of
cell cycle and differentiation and the MEK1/2 and MEK5 MAPK signaling pathways are
emerging targets for drug discovery. The MEK5-ERK5 pathway is an important
therapeutic target in many cancers as it has been shown to regulate tumor growth and
metastasis.90 Moreover, activation of the MEK5-ERK5 pathway, in response to inhibition
of the MEK1/2-ERK1/2 cascade, may mediate resistance to MEK1/2-ERK1/2 pathway
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inhibitors.91 MEK1/2 inhibitors trametinib and cobimetinib are FDA-approved for the
treatment of NSCLC and melanomas; however, MEK5/ERK5 pathway inhibitors are only
currently used as experimental tools. Our research interests include the development of
selective novel pharmacological inhibitors of the MEK5-ERK5 pathway.
Activation of MAPK results in phosphorylation of downstream targets ERK1/2 and
ERK5, which can activate gene transcription of epithelial to mesenchymal transition
(EMT) regulators such as ZEB1, Snail, and Vimentin.90, 92 EMTs play an instrumental role
in cancer metastases.93-94 Therefore, inhibition of EMT is emerging as a target to
attenuate the aggressive characteristics of cancer cells. Induction of the mesenchymal to
epithelial transition (MET), the reverse of EMT, by small molecules, represents a practical
and viable approach for treating the cancers which have a mesenchymal phenotype.
While small-molecule kinase inhibitors mostly target the ATP-binding pocket, several
novel diphenylamine derivatives were synthesized to target an allosteric site of MEK5
(Figure 3.1 A).83 Allosteric inhibition of kinases may offer reduced resistance and greater
kinase selectivity.95
While the kinase domain of ERK1/2 and ERK5 proteins share about 60%
sequence homology, ERK5 differs from ERK1/2 in its N-terminal domain, which harbors
the nuclear localization sequence, and a unique allosteric binding pocket (Figure 3.1 AB). Novel MEK5 pathway inhibitors were synthesized by making structural modifications
of the lead MEK1/2 inhibitor, PD325901. Compound 1, a dual MEK1/2 and MEK5
inhibitor, was identified to target the EMT axis in MDA-MB-231 cells (Figure 3.2). The
highly invasive MDA-MB-231 cell line (TNBC) was selected, as it consists of more than
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90% of high CD44+/CD24−/low stem cells,96 and has high expression of mesenchymal
markers including vimentin, SNAIL, SLUG, and ZEB1.

Figure 3.1: Drug discovery. A. ATP and Type III binding sites of the MEK1 crystal
structure (PDB ID:3EQC) superimposed on a homology model of MEK5. ATP is shown
as space filling and compound 1 is shown as a stick representation in the proposed type
III binding site. B. Phylogram analysis of MEK isoforms; MEK5 is most closely related to
MEK1 and MEK2.83
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Structural variants of compound 1 were synthesized to identify the functional
groups responsible for induction of MET. We examined two experimental endpoints to
quantify the activity of diphenylamine derivatives for a inducing mesenchymal to epithelial
transition in MDA-MB-231 cells after treatment with structural analogs of compound 1: (i)
upregulation of the epithelial marker E-cadherin examined via western blotting and (ii)
phenotypic switch from mesenchymal to epithelial as indicated by a decrease in spindle
index (SI) and an increase in % cells with SI<3. The lead molecule, compound 1, was
found to decrease spheroid formation, cell migration, and cell proliferation in TNBC (MDAMB-231 and BT-549) and tamoxifen-resistant (TAMR) MCF-7 breast cancer cells.
Compound 1 also decreased ZEB1, Snail, SOX2, and Vimentin (mesenchymal and stem
cell markers) in MDA-MB-231 cells.
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Figure 3.2. Compound 1 (SC-1-151), a dual ERK1/2 and ERK5 inhibitor induces a
phenotypic switch in MDA-MB-231 cells. (A.) Structure of Compound 1. (B.)
Compound 1 inhibits ERK1/2 and ERK5 phosphorylation in MDA-MB-231 cells. Data
represent the +/- SEM of three different experiments determined by two-way ANOVA with
the Bonferroni post hoc test. *p<0.05; **P<0.01; ***P<0.001; ****P<0.0001; vs untreated
respective control group determined; #P<0.001, ####P<0.0001; vs untreated control at 0
hour determined by two-way ANOVA with the Bonferroni post hoc test. (C.) Compound 1
was serendipitously identified to induce a phenotypic switch from mesenchymal to
epithelial in MDA-MB-231 cells.
3.2 Hypothesis: Novel diphenylamine analogs will induce MET and decrease spheroid
formation, cell migration, and proliferation in triple-negative and TAMR breast cancer
cells.
3.3 Results:
3.3.2 Structure-activity relationship of novel diphenylamine analogs for MET
induction:
MDA-MB-231 cells were treated with the diphenylamine structural variants (Figure
3.3) at a concentration of 1 μM for 5 days. Increase in E-cadherin protein expression and
change in morphology from mesenchymal to epithelial were the primary endpoints to
study the effect on MET. E-cadherin expression order for amide variations at R1 (Figure
3.3) was NHCH3 (2) > NH2 (1) > 4-Boc-piperazine (16) > piperazine (15) > N(CH3)2 (5)
> N(C2H5)2 (4) > NHC2H5 (3) > N(CH3)C2H4N(CH3)2 (17) > 4-methylpiperazine (13;
Table 3.1) at R1. Compounds 1, 2, 15, and 16 caused a >9-fold increase compared to
DMSO. The 4-methyl piperazinyl analog 13 was 3-fold less active compared to compound
1. Removal of the 4-methyl group led to a 3-fold improvement in E-cadherin induction
(compound 13 vs. 15). The 4-Boc protected derivative 16 was 3-fold more active than 13.
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Compounds 15 and 16 were equally effective as compound 1. The acid (7) was 2-fold
less active, and ester 6 was about 5-fold less potent compared to 1. Both basic side chain
amides (15) and neutral amides (1-5, 16) were active in inducing MET consistent with
significant functional group tolerance attached to the amide group.
Replacement of the R2 and R3 fluoro atoms with hydrogen atoms led to a >3-fold
decrease in the E-cadherin expression (1 vs. 8). Similarly, replacing the R4 hydrogen with
a methyl group led to a >3-fold reduction in the E-cadherin expression (1 vs. 9).
Substituting the iodo atom (11) at R6 or the fluoro atom (12) at R5 with hydrogen results
in a 3-fold decrease in E-cadherin expression as compared to 1. Removal of both the
groups (10) did not increase E-cadherin expression. These data indicate that the fluorine
atom at R5 and the iodine atom at R6 are essential for MET induction. The derivatives
with substitutions at the R7 position were found to be inactive (19–21). The structural
variations on the diphenylamine core, increase in E-cadherin expression, SI values, and
% cells with SI<3 are summarized in table 3.1.
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Aniline substitution
Acyl side-chain
variations

R1

O

R2

R4
N

R5

R7

R3

R1

Variations analyzed
= -OH
-OCH
-N(CH3)C2H4N(CH3)2
-NH 3
N
N CH3 (4-methylpiperazine)
2
-NHCH
-NHC 3
H
-N(CH2 5
-N(C 3)2
2H 5) 2

Arene #2
variations

R6

R2 = R3

Arene #1
variations

R4
R5
R6
R7

N

N Boc (4-Boc-piperazine)

N

NH

(piperazine)

= -H, -F

= -H, -CH

= -H, -F

3

= -H, -I
= -H, -Br, -N

3

Figure 3.3. Diphenylamine structural variants.

#

Side chain
R1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

-NH2
-NHMe
-NHEt
-N(C2H5)2
-N(CH3)2
-OMe
-OH
-NH2
-NH2
-NH2
-NH2
-NH2
4-methylpiperazine
4-methylpiperazine
-piperazine
4-Boc-piperazine
-N(CH3)C2H4N(CH3)2
4-methylpiperazine
4-methylpiperazine
-NHEt
4-methylpiperazine
DMSO

Arene #1
R2
R3

-F
-F
-F
-F
-F
-F
-F
-H
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F

-F
-F
-F
-F
-F
-F
-F
-H
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F
-F

R4
-H
-H
-H
-H
-H
-H
-H
-H
-CH3
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H

Arene #2
R5
R6

R7

-F
-F
-F
-F
-F
-F
-F
-F
-F
-H
-F
-H
-F
-F
-F
-F
-F
-H
-H
-H
-H

-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-H
-N3
-N3
-Br

-I
-I
-I
-I
-I
-I
-I
-I
-I
-H
-H
-I
-I
-H
-I
-I
-I
-H
-H
-H
-H
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Ecadherin
(Fold
change ±
S.E.M.)a
10.5 ± 3.5
12 ± 4.6
4.9 ± 1.9
6.1 ± 2.1
7.6 ± 0.5
2.3 ± 0.7
4.5 ± 2.05
2.9 ± 1.4
2.8 ± 1.1
1.3 ± 0.1
4.3 ± 1.5
3.1 ± 0.6
3.4 ± 0.8
1.1 ± 0.2
9.1 ± 2.2
9.9 ± 4.1
4.3 ± 3.3
1.7 ± 0.47
1.6 ± 0.90
0.77 ± 0.01
1.6 ± 0.88
1

p-value

S.I.
± %
cells
S.E.M.
with SI<3
± S.E.M.

0.012
0.002
0.001
<0.0001
<0.0001
0.015
0.009
0.062
0.008
0.002
0.004
<0.0001
<0.0001
0.550
<0.0001
<0.0005
0.048
0.0009
0.2786
<0.0001
0.2394

2.2 ± 0.1
2.7 ± 0.2
2.5 ± 0.4
2.6 ± 0.2
2.6 ± 0.2
2.9 ± 0.1
2.8 ± 0.1
3.3 ± 0.2
3.3 ± 0.4
3.9 ± 0.3
3.6 ± 0.1
2.4 ± 0.1
2.8 ± 0.1
3.5 ± 0.1
1.9 ± 0.2
2.8 ± 0.1
3 ± 0.2
3.6 ± 0.1
3.5 ± 0.2
3.4 ± 0.2
3.8 ± 0.2
4.2 ± 0.4

85.9 ± 3.4
64.6 ± 0.4
81.9 ± 7.8
67.5 ± 6.2
73.1 ± 5.5
62.2 ± 2.4
66.1 ± 6.4
61.5 ± 5.1
52.4 ± 12
29.7 ± 1.1
44.9 ± 0.3
83.1 ± 1.8
70.7 ± 2.1
41.3 ± 4.7
86.3 ± 7.7
68.3 ± 4.7
59.3 ± 6.1
55.8 ± 5.2
47.4 ±2.9
47.1 ± 6.7
37.6 ± 5.5
30.5 ± 4.8

Table 3.1: Effect of diphenylamine analogs on E-cadherin expression, spindle
index, and % cells with S.I.<3 in MDA-MB-231 cells. MDA-MB-231 cells were treated
with compounds 1-20 at 1μM concentration for 5 days. Data represent mean ± SEM. ECadherin was normalized to a-tubulin, and fold change is compared to DMSO. One-way
ANOVA with Bonferroni post-hoc comparison analysis was performed where the
compounds were compared to the DMSO control and to each other; compounds 1 and 2
were found to be statistically significant compared to the DMSO control group (P < 0.05).
We missed significance across groups because there was large difference between the
minimum and the maximum effect produced by the different compounds. Therefore, we
switched to performing t-test and compared each compound individually to the DMSO
control group. aData represent the ± SEM of three different experiments determined by
unpaired two-tailed Student’s t-test (n = 3).

Figure 3.4. Increase in E-cadherin expression significantly correlates with the
percentage of cells with SI<3. A positive correlation between E-cadherin protein
expression, compared to DMSO and an increase in percentage of cells with SI < 3 was
observed. Data was analyzed by two-tailed Pearson correlation. The correlation
coefficient (rP) and significance (p-value) are indicated on the scatter plot.
3.3.3 Increase in E-cadherin positively correlates with an increase in % cells with
SI<3
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MET is characterized by a morphological switch from a spindle-like phenotype to
a cobblestone-like phenotype. To determine cell morphology, crystal violet staining was
performed after 5 days of treatment with the diphenylamine analogs. To quantitate the
phenotypic transition, spindle index (SI) was determined as the length to width ratio of
each cell. Cells with a SI < 3 were considered epithelial.84 The compounds that led to an
increase in E-cadherin protein expression also altered the morphology of MDA-MB-231
cells from mesenchymal to epithelial, as measured by a reduction in the spindle index
value. The compounds that increased E-cadherin expression by at least 3-fold and that
displayed >50% of the cells with a SI < 3 were described as MET activators (Figure 3.4).
The most potent MET activators from this series were analogs 1, 2, 15, and 16
(Table 3.1, and Figure 3.4) inducing >9-fold increase in E-cadherin compared to DMSO
(vehicle) and increasing % cells with SI < 3 by greater than 50%. Based on the primary
endpoints of E-cadherin induction and spindle index, analogs 1 and 15 showed the best
profile in increasing E-cadherin (10.5 and 9.1 fold increase, respectively vs. 1 with
DMSO), percentage of cells with SI < 3 (85.9 and 86.3%, respectively vs. 30.5% with
DMSO), and decreasing SI (2.2 and 1.9 fold, respectively vs. 4.2 with DMSO). Similar to
diphenylamine analogs, tolfenamic acid and thyroid hormones contain two aromatic rings
connected by a single heteroatom. Therefore, these compounds were evaluated for Ecadherin expression and cell morphology. There was no increase in E-cadherin after
treatment with NSAIDS or decrease in cell viability (Figure 3.5). The morphology of cells
after treatment with the diphenylamine analogs is shown in Figure 3.6.
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Figure 3.5 NSAIDS and thyroid hormones do not induce MET in MDA-MB-231 cells
(A) E-Cadherin expression did not increase after treatment with NSAIDS. The compounds were
treated for 5 days at 1μM concentration. (B.) NSAIDS did not inhibit cell viability. Data
represent the ± SEM of three different experiments. *P<0.05 vs control group determined
by one-way ANOVA with the Bonferroni post hoc test.

Analogs 1, 2, 15 and 16 were further tested in spheroid viability assays. Analog 18
was included as a negative control. EMT can cause resistance to anchorage-independent
death “anoikis,” and increase in spheroid-forming ability.97 To evaluate the effect of
diphenylamines on spheroid formation, MDA-MB-231 cells were grown in ultra-lowattachment plates (Figure 3.7A). Compound 1 significantly decreased spheroid viability
compared to DMSO, compound 15, and compound 18 (Figure 3.7A and B). Therefore,
we concluded that compound 1 was the best in-series and the effects of compound 1
were evaluated on cell migration and proliferation.
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Figure 3.6. MDA-MB-231 cell morphology after treatment with diphenylamine analogs. MDA-MB-231 cells were
treated with 1 μM compound or vehicle for 5 days. Crystal violet staining was performed. Images were taken to examine
cell morphology.

Figure 3.7. Compounds 1 and 15 decrease spheroid viability in MDA-MB-231 cells.
(A) Spheroid formation in MDA-MB-231 cells after treatment with DMSO or compounds
18, 15, and 1 for 7 days of treatment. (B) Quantification of the spheroid viability in MDAMB-231 cells, values indicate ± SEM of three experiments run in triplicate. ***p < 0.001,
****p < 0.0001 vs. control group, ###p < 0.001 compound 1 vs. compound 18 #p < 0.05
compound 1 vs. compound 15 determined by one-way ANOVA with the Bonferroni post
hoc test in MDA-MB-231 cells.
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3.3.4 Compound 1 increases E-cadherin and decreases mesenchymal markers in
TNBC and TAMR cells
Next, we wanted to examine the effect of the lead compound on more EMT
markers, models, and in functional assays. We included another TNBC cell line BT-549
and TAMR MCF-7 cells with a mesenchymal phenotype. When compared to the epithelial
phenotype of parental MCF-7 cells, TAMR MCF-7 cells do not express E-cadherin (Figure
3.8). These observations were consistent with previous studies, which have shown that
tamoxifen resistance leads to EMT in MCF-7 cells.98-99 MDA-MB-231, BT-549, and TAMR
MCF-7 cells were treated with compound 1 (Figure 3.9) for 5 days and the lysates were
collected for western blotting. EMT markers, including the epithelial marker E-cadherin, a
downstream target of ERK5, fos-related antigen (FRA-1), and mesenchymal markers
ZEB1, vimentin, and snail were evaluated in TNBC and TAMR MCF-7 cells. Compound
1 attenuated the expression of vimentin and stemness marker SOX2 in cells that
underwent MET (Figure 3.9B-C).

Figure 3.8. Tamoxifen resistance is associated with EMT in ER+ MCF-7 cells. (A)
Cell morphology of WT and TAMR MCF-7 cells. (B) E-cadherin expression in TAMR MCF7 is significantly decreased compared to WT MCF-7 cells.
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Compound 1 increased E-cadherin expression, decreased ZEB1, Snail, and FRA1 activation in MDA-MB-231, BT-549, and TAMR MCF-7 cells (Figure 3.9A). Compound
1 decreased vimentin expression in MDA-MB-231 and TAMR MCF-7 cells, but not in BT549 cells.
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Figure 3.9. Compound 1 decreases mesenchymal markers and increases Ecadherin expression in breast cancer cells (A) Compound 1 decreases EMT markers,
FRA-1 activation, and induces E-cadherin in TNBC and TAMR MCF-7 cells. (B)
Compound 1 attenuates vimentin expression in MDA-MB-231 cells. (C) Compound 1
attenuates SOX2 expression in MDA-MB-231 cells.
3.3.5 Lead compound 1 decreases cell migration, colony formation, and cell
proliferation in MDA-MB-231 cells.
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H.

Figure 3.10. Compound 1 decreases cell migration, colony formation, and cell
proliferation in MDA-MB-231 cells. (A, B) Wound closure was measured as a
percentage of untreated DMSO control group. *p < 0.05 vs. DMSO control group
determined by one-way ANOVA with the Bonferroni post hoc test. (C) Compound 1
inhibited MDA-MB-231 colony formation after 14 days of treatment in a concentrationdependent manner. Data represent ± SEM of experiments run in triplicate, *p < 0.05; **p
< 0.01 vs. DMSO control group determined by one-way ANOVA with the Bonferroni post
hoc test. (D) Immunofluorescence staining of Ki67, Hoechst, and a-tubulin in MDA-MB231 cells treated with DMSO or compound 1 (1μM), for 72 hours, scale bar 200μm. (E)
Ki67+ cells decreased with increasing concentrations of compound 1. (F) Decrease in
Hoechst+ cells with increasing concentrations (0.1, 1, 10μM) of compound 1. (G) The
proliferative fraction calculated as the ratio of Ki67+ cells to Hoechst+ cells at increasing
concentration. Data represent ± SEM of three different experiments. **p < 0.01; ***p <
0.001 vs. control group determined by one-way ANOVA with the Bonferroni post hoc test.
(H) Pictures of colonies after treatment with DMSO or Compound 1.
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Treatment with compound 1 produced a concentration-dependent reduction in cell
migration (Figure 3.10A-B), and colony formation (Figure 3.10C) in MDA-MB-231 cells.
Immunofluorescence staining for Ki67 and Hoechst was performed to evaluate cell
proliferation in MDA-MB-231 cells. Compound 1 significantly decreased the number of
Ki67+ and Hoechst+ cells (Figure 3.10D-E) and the proliferative fraction determined as
the number of Ki67+/ number of Hoechst+ cells (Figure 3.10F). The effects of compound
1 were also evaluated on spheroid formation, cell migration, and proliferation in BT-549
TNBC cells and TAMR MCF-7 ER+ breast cancer cells.
3.3.6 Compound 1 inhibits spheroid formation, cell migration, and proliferation in
BT-549 and TAMR-MCF-7 cells.
BT-549 and TAMR-MCF-7 cells were treated with 0.1, 1, and 10 μM concentrations
of compound 1. Compound 1 produced a concentration-dependent decrease in spheroid
viability after 7 days in BT-549 cells (Figure 3.11A-B) and TAMR MCF-7 cells (Figures
3.11C-D). At 1 μM concentration, compound 1 decreased spheroid viability by 51.55 and
72.91% in BT-549 and TAMR MCF-7 cells, respectively. Compound 1 produced a
concentration-dependent decrease in cell migration and proliferation in BT-549 cells
(Figures 3.12A and C). There was a 67.9% reduction in cell proliferation at 10μM
concentration in BT-549 cells.
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Figure 3.11. Compound 1 inhibits spheroid viability in BT-549 and TAMR MCF-7
cells. (A) Spheroid formation in BT-549 cells after treatment with DMSO or compound 1
at 1μM concentration for 7 days, scale bar 1,000μm. (B) Quantification of the spheroid
viability in BT-549 cells after treatment with compound 1 at increasing concentrations (0.1,
1, 10 μM) after 7 days of treatment, data represents ± SEM *p < 0.05; ***p < 0.001 vs.
control group determined by one-way ANOVA with the Bonferroni post hoc test in BT-549
cells. (C) Spheroid formation in TAMR MCF-7 after treatment with DMSO or compound 1
at 1μM concentration for 7 days, cells scale bar 1,000μm. (D) Quantification of the
spheroid viability after treatment with compound 1 at increasing concentrations (0.1, 1,
10 μM) after 7 days of treatment in TAMR MCF-7 cells, values indicate ± SEM of three
experiments run in triplicate. *p < 0.05; ***p < 0.001 vs. control group determined by oneway ANOVA with the Bonferroni post hoc test.
In TAMR MCF-7 cells, compound 1 produced a concentration-dependent
decrease in cell migration (Figure 3.13A-B). Additionally, treatment with compound 1
significantly decreased the number of Ki67+ (Figure 3.13D) and Hoechst+ (Figure 3.13E)
cells. There was 79.7% decrease in the proliferative fraction at 1 μM (Figure 3.13F).
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Figure 3.12. Compound 1 inhibits cell migration and proliferation in BT-549 cells.
(A) Wound closure was measured after treatment with increasing concentrations (0.1, 1,
10μM) of compound 1. The data is presented as a percentage of untreated DMSO control
group. *p < 0.05 vs. control group determined by one-way ANOVA with the Bonferroni
post hoc test (BT-549 cells). Compound 1 inhibits cell proliferation in BT-549. (C)
Immunofluorescence staining of Ki67, Hoechst, and a-tubulin in BT-549 cells treated with
DMSO or compound 1 (1μM), for 72 hours, scale bar 200μm. (B) Ki67+ cells decreased
with increasing concentrations (0.1, 1, 10μM) of compound 1. (C) Decrease in Hoechst+
cells with increasing concentrations (0.1, 1, 10μM) of compound 1. (D-F) The proliferative
fraction calculated as the ratio of Ki67+ cells to Hoechst+ cells at increasing
concentrations (0.1, 1, 10μM) of compound 1. Data represent ± SEM of three different
experiments. *p < 0.05 vs. control group determined by one-way ANOVA with the
Bonferroni post hoc test.

52

Figure 3.13. Compound 1 inhibits cell migration and proliferation in TAMR MCF-7
cells. (A) Wound closure was measured after treatment with increasing concentrations
(0.1, 1, 10μM) of compound 1. The data is presented as a percentage of DMSO control
group. *p < 0.05; ***p < 0.001 vs. control group determined by one-way ANOVA with the
Bonferroni post hoc test (TAMR MCF-7 cells). Compound 1 inhibits cell proliferation in
TAMR MCF-7 cells (C) Immunofluorescence staining of Ki67, Hoechst, and a-tubulin in
TAMR MCF-7 cells treated with DMSO or compound 1 (1 μM), for 72 hours, scale bar
200 μm. (D) Ki67+ cells decreased with increasing concentrations (0.1, 1, 10 μM) of
compound 1. (E) Decrease in Hoechst+ cells with increasing concentrations (0.1, 1, 10
μM) of compound 1. (TAMR MCF-7 cells) (F) The proliferative fraction calculated as the
ratio of Ki67+ cells to Hoechst+ cells at increasing concentrations (0.1, 1, 10 μM) of
compound 1 (TAMR MCF-7 cells). Data represent ± SEM of three different experiments.
*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001 vs. control group determined by oneway ANOVA with the Bonferroni post hoc test.
3.4 Discussion
Our findings suggest that at the R1 position the diphenylamine core, amides
(primary, secondary, and tertiary) induced E-cadherin to a greater fold compared to ester
(6) or acid (7). The R1 position showed tolerance toward steric bulk and charge. At R2
and R3, the removal of both fluoro groups reduced the E-cadherin expression by 3.5 fold
(8 vs. 1). We speculate that the electron-withdrawing fluorine atoms either polarize the
arene 1 ring, potentiating its interactions with its biological target (p- p stacking
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interactions and/or ion-dipole interactions) or the fluorine atom may act as hydrogen bond
acceptor (HBA) (32). At R4 position, the replacement of the hydrogen atom (1) with a
methyl group (9), led to a 4-fold reduction in E-cadherin expression. These data suggest
that the R4 hydrogen participates in an intramolecular hydrogen bond with the carbonyl
group attached to R1, forming a conformation favoring MET. The N-methyl group of
analog 9 may disrupt the intramolecular hydrogen bond, leading to the corresponding
decrease in E-cadherin expression.
By substituting the fluorine at R5 and iodine at R6 with hydrogen atoms, there was
no increase in E-cadherin expression (analog 10 vs. 1). We speculate that the fluoro
group at R5 may: a) decrease the pKa of the R4 hydrogen making it a better hydrogen
bond donor to facilitate MET induction, and/or b) increase the lipophilicity of the molecule;
improving hydrophobic interactions with the biological target(s) (33, 34).
The iodo group at R6 is a large group, which can undergo hydrophobic interactions
and/or can form a halogen bond. At R7 position all the three analogs (19- 21) were
inactive in inducing MET. An important contributing factor could be that these compounds
do not have any substitutions at R5 and R6 positions. Moreover, they did not possess a
free NH2 group at R1, which may contribute to their inability to induce MET. Overall, our
initial structure-activity study suggests that different substitutions at R1 are tolerated and
this position can be exploited toward improving potency or deducing the molecular target
of diphenylamines. Removal/change of substituents at R2-R7 positions are not tolerated.
Therefore, they may represent the minimum pharmacophore required for MET activity.
There was a positive correlation between increase in E-cadherin expression and the
percentage of cells with SI < 3, which strengthens the structure-activity relationship. This
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also suggests that spindle index measurement could be a reliable quantitative analysis
for cells that undergo morphological transitions.
NSAIDS (tolfenamic acid, sulindac, and meloxicam) and thyroid hormones
(triiodothyronine and thyroxine) bear structural similarity to the diphenylamine
compounds, but they did not induce MET in MDA-MB-231 cells (Figure 3.5). One reason
could be both NSAIDs and thyroid hormones do not have the minimum pharmacophore
required for inducing MET. Also, the in-house diphenylamines inhibit MEK1/2 and MEK5;
since the biological targets of the two drug classes under study are different, this may
explain why NSAIDS and thyroid hormones did not induce MET.
MDA-MB-231 cells cultured in low-attachment plates were examined to determine
the effect of compounds 1, 15, and 18 on spheroid formation. The selection of compounds
was made based on their ability to induce MET: low (compound 18)—high (compounds
1 and 15) and differences in their structures (primary vs. tertiary amides at R1). Two-way
ANOVA with Bonferroni post-hoc test revealed that compound 1 was the most effective
in inhibiting spheroid growth. One of the reasons why compound 1 was more effective is
because compound 1 is a dual MEK1/2 and MEK5 inhibitor, but compounds 15 and 18
inhibit MEK1/2 and MEK5, respectively.83 Therefore, the effects of compound 1 were
examined on cell migration and proliferation. Moreover, the effect of compound 1 was
characterized in two additional breast cancer cell models, which have a mesenchymal
phenotype: TNBC cell line BT-549 and tamoxifen-resistant MCF-7 cell line.
Since EMT triggers cell migration and motility, the scratch assay/ wound closure
assay was performed to examine cell migration. Cells at the border of the wound are
known to be enriched in pathways involved in cell migration and not proliferation.86 Cells
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that undergo MET may re-acquire the proliferative potential to promote metastatic
colonization.100 Therefore, we examined the effect of compound 1 on cell proliferation.
Compound 1 significantly decreased cell migration and proliferation in diverse breast
cancer models. Compound 1 also decreased spheroid formation in MDA-MB-231, BT549 TNBC, and TAMR MCF-7 cells including spheroid formation, cell migration, and cell
proliferation. In summary, to our knowledge, this is the first time that novel inhibitors of
MEK1/2 and/or MEK5 pathways were examined to influence EMT reversal in triplenegative and tamoxifen resistant breast cancers. Compound 1, a novel dual MEK1/2 and
MEK5 inhibitor was effective in inducing MET in diverse breast cancer subtypes,
decreasing proliferation, migration, and spheroid formation.
In conclusion, EMT is a crucial process for cancer progression and metastases.
Therefore, a reversal of the EMT to induce an MET may decrease metastases to allow
targeting of the less aggressive epithelial cancer cells in situ. Through analog-based drug
design, analogs that potentiate MET were discovered. Compound 1 was identified as the
lead, as treatment with this compound increased E-cadherin expression and caused
morphological change from mesenchymal to epithelial phenotype. Moreover, compound
1 attenuated the migratory and proliferative properties of TN and TAMR breast cancer
cells. In the next chapters, we will discuss about independent and overlapping functions
of ERK1/2 and ERK5 pathways on EMT/MET, nuclear localization of ERK, and migration,
proliferation, and spheroid formation. Moreover, several combination strategies of
compound 1 with AKT or epigenetic inhibitors will be discussed.
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Chapter 4: Targeting the ERK5 and/or ERK1/2 pathways reverses EMT, decreases
proliferation, migration, and spheroid formation in triple-negative and tamoxifenresistant breast cancer cells
4.1 Introduction
Metastases account for ~90% of cancer related human deaths.101 An increasing
body of evidence suggests that activation of ERK1/2 and ERK5 signaling is a marker for
node metastases and a predictor of poor responses to hormone therapy such as 4OHT.102-104 Moreover, activation of intracellular signaling pathways, such as the ERK
MAPK pathways, has been shown to mediate tumorigenesis in TNBCs and tamoxifen
resistant breast cancers.105-106 For example, ERK1/2 activation is known to mediate EMT
in several cancer models18, 92, 107-108, and overexpression of the newest member of the
MAPK family, ERK5, induces EMT and hormone-independent growth of breast cancer.104
Although activation of the ERK1/2 and ERK5 pathways have been shown to mediate
EMT, the effect of ERK1/2 and ERK5 inhibition on inducing MET, the reverse of EMT, is
poorly understood in cancer.
To identify the link between MAPK pathways and EMT, MAPK3 (ERK1),
MAPK1(ERK2), and MAPK7 (ERK5) gene expression was correlated with EMT markers
CDH1, ZEB1, or VIM in tumors derived from TNBC patients using publicly available
datasets. Additionally, overall survival in patients with inflammatory breast cancer was
plotted against ERK1, ERK2, or ERK5 gene expression using publicly available datasets.
TNBCs account for about 40% of all inflammatory breast cancers.109
We hypothesize that inhibition of the ERK1/2 and ERK5 pathways is a relevant
strategy to induce a MET in TNBCs. To test this hypothesis, we examined the effects the
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ERK1/2 and ERK5 pathways on the MET using pharmacological inhibitors of MEK1/2 and
ERK5, trametinib and XMD8-92, respectively. Since the location-specific roles of ERK1/2
and ERK5 with respect to EMT are less well-understood, we examined the effect of
XMD8-92 and trametinib on nuclear localization of ERK1/2 and ERK5. To validate the
inhibitor data, the effect of lentivirus-mediated activation or inhibition of ERK1/2 and ERK5
pathway components on the MET was examined. Cell morphology and protein expression
of epithelial and mesenchymal markers, E-cadherin and ZEB1 were examined and
activation of ERK1/2, ERK5, and RSK, a downstream target of MAPK signaling, were
evaluated. The effects of XMD8-92 and trametinib were evaluated on cell migration and
cell proliferation in MDA-MB-231, BT-549 TNBC cells, and tamoxifen-resistant (TAMR)
MCF-7 breast cancer cells. Moreover, TU-BcX-4IC patient-derived primary TNBC cells
were included to enhance the translational relevance of our study.
4.2 Hypothesis
Inhibition of ERK1/2 and/or ERK5 pathways will induce MET and decrease cell migration,
proliferation, and spheroid formation in TNBC and TAMR breast cancer cells.
4.3 Results
4.3.1

ERK1, ERK2, and ERK5 expression correlates with EMT markers and is

associated with poor patient survival in breast cancer
Since the effect of ERK1/2 and ERK5 pathways on EMT is less well-understood in
TNBCs, we first used publicly available datasets from Purrington, K. S. and colleagues110
to correlate MAPK3 (ERK1), MAPK1 (ERK2), or MAPK7 (ERK5) gene expression with
EMT markers CDH1 (E-cadherin), ZEB1, or vimentin in primary, invasive tumors derived
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from African-American TNBC patients (Figure 4.1). There was a moderate to strong
correlation between MAPK3, MAPK1, and MAPK7 with mesenchymal markers ZEB1 and
vimentin. Using Kaplan-Meier survival analysis to examine the relationship between
ERK1/2/5 expression and patient survival in inflammatory breast cancer (public datasets
from Bertucci et al.109), MAPK3, MAPK1, or MAPK7 gene expression were found to be
associated with poor patient survival (Figure 4.2). Overall, these data suggest that ERK1,
ERK2, and ERK5 may be important therapeutic targets in breast cancer.
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Figure 4.1 Correlation of ERK1, ERK2, or ERK5 with EMT markers in tumors derived
from TNBC patients. Gene correlation between (A) MAPK3(ERK1), (B) MAPK1(ERK2),
or (C) MAPK7 (ERK5) and EMT markers CDH1, ZEB1, or VIM was plotted using R2:
Genomics
analysis
and visualization platform (https://hgserver1.amc.nl/cgibin/r2/main.cgi). Datasets were exported from Tumor Breast (triple negative) - Purrington
- 226 - rma_sketch - hugene21t.

Figure 4.2 MAPK3, MAPK1, and MAPK7 expression correlates with poor patient
survival in breast cancer. Disease free survival was analyzed using R2: Genomics
analysis and visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).
Datasets were exported from Tumor Breast (MDC) Bertucci - 266 - MAS5.0 - u133p2.
4.3.2 Pharmacological inhibition of the ERK1/2 and/or ERK5 pathways induces MET
in TNBC and TAMR breast cancer
Since ERK1, ERK2, and ERK5 were identified as important targets in breast
cancer and their gene expression was found to correlate with EMT markers,
pharmacological inhibitors of these pathways were utilized to examine their effect on
MET, the reverse of EMT. MDA-MB-231, BT-549, TU-BcX-4IC TNBC, and TAMR cells
were treated with increasing concentrations of XMD8-92, an ERK5 and BRD4 inhibitor,
and trametinib, a MEK1/2 inhibitor, for 72 hours. Following treatment with the inhibitors,
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the morphology of the breast cancer cells was examined. Trametinib induced a
morphological switch from mesenchymal to epithelial in all the cell lines, while XMD8-92
only induced this morphological change in MDA-MB-231 cells (Figures 4.3).
To confirm the morphological switch, we examined the expression of the epithelial
and mesenchymal markers, E-cadherin and ZEB-1, respectively. Trametinib increased
E-cadherin expression in MDA-MB-231, BT-549, TU-BcX-4IC, and TAMR cells and
decreased ZEB-1 expression in MDA-MB-231 and TU-BcX-4IC cells. XMD8-92 (10uM)
decreased the expression of E-cadherin and ZEB1 only in MDA-MB-231 cells (Figure
4.3A). WT-MCF-7 epithelial cells were included as a control to study EMT. Treatment of
the WT-MCF-7 cells with XMD8-92 or trametinib did not alter cell morphology or Ecadherin expression (Figure 4.4A, B). p-P90RSK, a downstream target of MAPK pathway
was undetected in WT-MCF-7 cells, indicating that RSK activation may be a major event
in regulating EMT associated with tamoxifen-resistance (Figure 4.4C). Cells that undergo
EMT may exhibit a complete cadherin switch, which is characterized by a complete loss
of E-cadherin; however, partial EMT state is characterized by co-expression of epithelial
and mesenchymal markers.111 The extent of MET induced by the inhibitors was
determined by examining the correlation between E-cadherin and ZEB1 expression
(Figure 4.5). A greater than 3-fold change in protein expression is indicative of a
significant difference. Therefore, treatment that induced E-cadherin expression by greater
than 3-fold and decreased ZEB1 by greater than 0.3-fold was determined to induce a full
MET, whereas treatment that induced a 3-fold increase in E-cadherin expression or 0.3fold was determined to induce a partial MET. Trametinib induced a full MET in MDA-MB-

61

231 and TAMR MCF-7 cells at low and high doses, whereas it induced a partial MET in
BT-549 cells (Figure 4.5).
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Figure 4.3 ERK1/2 and ERK5 pathway inhibition induces MET in TNBC and TAMR MCF-7 cells. Cells were treated with XMD892 and trametinib at increasing concentrations for 72 hours. Cell morphology (20X magnification) and EMT markers E-cadherin and
ZEB1 were examined in (A) MDA-MB-231, (B) BT-549, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells. Data represent the ± SEM of
three different experiments for each inhibitor compared to DMSO control. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control
group determined by one-way ANOVA with the Bonferroni post hoc test.

Figure 4.4 Evaluation of cell morphology, E-cadherin and p-P90RSK levels in WTMCF-7 cells. (A) Kinase inhibitors do not alter the phenotype (20X magnification) or (B)
E-cadherin expression in ER+ MCF-7 epithelial cells. (C) p-P90RSK was not detected in
WT MCF-7 cells.
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Figure 4.5 Correlation to determine extent of MET induced by trametinib or XMD8-92. (A)
MDA-MB-231, (B) BT-549, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells.

4.3.3 Role of kinases in MET
ERK1/2 and ERK5 pathways are important regulators of EMT. To examine a role
for the MAPK pathways in MET, ERK1/2, ERK5, and RSK activation in MDA-MB-231,
BT-549, TU-BcX-4IC and TAMR MCF-7 cells were examined after 72 hours of treatment
of trametinib or XMD. As expected, trametinib significantly decreased ERK1/2 and RSK
phosphorylation in the panel of breast cancer cell lines. Interestingly, trametinib (0.1 μM)
decreased ERK5 phosphorylation in MDA-MB-231 cells. XMD8-92 decreased ERK5
phosphorylation in MDA-MB-231 cells by 40% and 65% at 1 and 10 μM concentrations,
respectively (Figure 4.6A). In contrast, XMD8-92 did not decrease ERK5 activation in
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BT-549, TU-BcX-4IC, and TAMR cells, (Figure 4.6 B, C, D). XMD8-92 decreased RSK
phosphorylation by ~ 40% at all concentrations in MDA-MB-231 cells and at the lowest
concentration in BT-549 cells. Overall, these findings that ERK1/2 and ERK5 activities
are differentially modulated by kinase inhibitors, indicating involvement of crosstalk
mechanisms between these pathways in diverse breast cancer models.
Cells were also treated with trametinib and XMD8-92 for shorter time points to
determine the effect of the inhibitors on EGF-mediated stimulation of the MAPK pathways.
This is a relevant assay to examine specificity of kinase inhibitors. Following serum
starvation for 18-24 hours, cells were treated with an inhibitor for 30 minutes, and then
with epidermal growth factor (EGF) for 15 minutes. XMD8-92 significantly decreased
ERK5 phosphorylation, as compared to DMSO+EGF treatment control in MDA-MB-231
and TAMR MCF-7 cells. Interestingly, in MDA-MB-231 and TAMR-MCF-7 cells, XMD892 had the opposite effect on ERK1/2 phosphorylation, such that ERK1/2 phosphorylation
was increased in BT-549 cells and decreased in TAMR-MCF-7 cells. In BT-549 and TUBcX-4IC cells, XMD8-92 did not significantly alter ERK5, ERK1/2, or RSK phosphorylation
induced by EGF. As expected, trametinib, a MEK1/2 inhibitor significantly decreased
activation of downstream targets of MEK1/2: ERK1/2 and RSK, in a dose-dependent in
response to EGF stimulation in BT-549, TU-BcX-4IC, and TAMR MCF-7 cells (Figure
4.7). However, trametinib significantly decreased EGF-mediated ERK1/2, ERK5, and
RSK phosphorylation in a dose-dependent manner in MDA-MB-231 cells (Figure 4.7).
These data indicate that trametinib is a dual inhibitor of ERK1/2 and ERK5 pathways in
MDA-MB-231 cells, but not in BT-549, TU-BcX-4IC, and TAMR MCF-7 cells. These data
also suggest that MEK1/2 may be upstream of ERK5 in MDA-MB-231 cells.
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Figure 4.6 Western blot analysis of MAPK downstream targets pERK5, pERK1/2, and pP90RSK in TNBC cells. (A) MDA-MB-231, (B) BT-549, (C) TU-BcX-4IC, and (D) TAMR MCF-7
cells. Data represent the ± SEM of three different experiments for each inhibitor compared to
DMSO control. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control group determined
by one-way ANOVA with the Bonferroni post hoc test.
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Figure 4.7 Evaluation of kinase inhibition under EGF stimulation. Cells were serum starved
for 18-24 hours and treated with the respective inhibitors for 30 minutes. EGF was added at a
100ng concentration for 15 minutes and western blot was performed on the lysates collected for
analysis of ERK5, ERK1/2, and P90RSK activation in (A) MDA-MB-231, (B) BT-549, (C) TU-BcX4IC, and (D) TAMR MCF-7 cells. Data represent the ± SEM of three different experiments for
each inhibitor compared to DMSO control. *p<0.05; **p<0.01; ****p<0.0001 vs DMSO control
group determined by one-way ANOVA with the Bonferroni post hoc test.

4.3.4 Effects of XMD8-92 and trametinib on cell migration and proliferation in breast
cancer
EMT is known to promote cell migration via downregulation of cell-cell adhesion
molecule E-cadherin.97, 112 To examine cell migration, a wound was introduced to the cell
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plates using a pipette tip. Wound closure was measured after treatment with DMSO or
inhibitors to determine the efficacy of MAPK inhibitors on cell migration. XMD8-92
decreased cell migration in MDA-MB-231 and TU-BcX-4IC cells at 10 μM concentration
(Figure 4.8A and C). Trametinib significantly decreased cell migration in MDA-MB-231,
BT-549, TU-BcX-4IC, and TAMR breast cancer cells (Figure 4.8A-D).
Cancer cells have high proliferation rates. To determine this proliferative fraction, cells
were stained with Ki67, a marker of proliferation. Proliferative fraction was calculated as
the ratio of number of Ki67+ cells to Hoechst+ cells. XMD8-92 produced a significant
decrease in proliferative fraction of MDA-MB-231, TU-BcX-4IC, and TAMR-MCF-7 cells
(Figure 4.8E, G-H), but not in BT-549 cells (Figure 4.8F). Trametinib had no effect on the
proliferative fraction in any of the cell lines.
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Figure 4.8. XMD8-92 and trametinib differentially decrease cell migration and proliferation in diverse breast cancer subtypes.
A) MDA-MB-231, (B) BT-549 cells, (C) TU-BcX-4IC, and (D) TAMR MCF-7 cells were treated with the kinase inhibitors and scratch
assay was performed (20X magnification). Cell migration was measured as a percentage of DMSO control group. Cell proliferation
assay was performed (E) MDA-MB-231, (F) BT-549, (G) TU-BcX-4IC and (H) TAMR MCF-7 (20X magnification). Data represent the ±
SEM of three different experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs. DMSO control group determined by one-way
ANOVA with the Bonferroni post hoc test.

4.3.5 Trametinib decreases nuclear ERK5 in MDA-MB-231, but not in BT-549 cells
ERK5 has a large C-terminal domain, which can facilitate its nuclear localization in
response to growth factors or via autophosphorylation. 113 ERK5 nuclear localization has
been linked with increase in cell proliferation.114 However, there are no studies that relate
the role of ERK5 localization to EMT. To examine the localization of ERK5 in TNBC with
distinct kinase mutation profiles, we selected two cell lines from our previously studied
cells: MDA-MB-231 are driven by a mutation in RAF leading to aberrant activation of the
MEK1/2-ERK1/2 and MEK5-ERK5 pathways, and BT-549 cells are driven by a loss of
function mutation in tumor suppressor phosphatase, PTEN, leading to subsequent
activation of the PI3K-AKT pathway.
MDA-MB-231 and BT-549 cells were treated with DMSO, 1 μM XMD, or 0.1 μM
trametinib for 72 hours. ERK5 was found to be localized in the nucleus and cytosol, but
active only in the nucleus of untreated MDA-MB-231 and BT-549 TNBC cells (Figure 4.9).
While ERK1/2 were found in both the nucleus and cytosol, ERK1/2 expression was higher
in the cytosol of the TNBC cells. In contrast to ERK5, ERK1/2 phosphorylation was noted
only in the cytosol of untreated MDA-MB-231 and BT-549 cells. Surprisingly, XMD8-92
did not decrease ERK5 activation in the nucleus of either cells. Trametinib decreased
total and phosphorylated ERK5 in the nucleus of MDA-MB-231 cells (Figure 4.9A, B), but
inhibited ERK5 only in the cytosol in BT-549 cells (Figure 4.9D). Trametinib significantly
decreased ERK1/2 activation in the cytosol in MDA-MB-231 and BT-549 cells. Total
ERK1/2 expression was not altered with either treatment in the cytosol of either cell line.
These findings indicate that decrease in total ERK5 expression in the nucleus may
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contribute to the MET-inducing potential of trametinib in MDA-MB-231 cells. Future
studies will be performed to examine the effect of ERK5 degradation on MET.
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Figure 4.9 Effect of XMD8-92 and trametinib on ERK5 and ERK1/2 activation in the nucleus and cytoplasm. (A) MDA-MB-231
nuclear fraction (B) MDA-MB-231 cytosolic fraction (C) BT-549 nuclear fraction (D) BT-549 cytosolic fraction. *p<0.05; ***p<0.001 vs
control group determined by one-way ANOVA with the Bonferroni post hoc test.

4.3.6 Diverse and converging roles of MEK1 and MEK5 on EMT and kinase
activation in TNBC cells
To further examine the roles of the ERK1/2 and ERK5 pathways on MET, MDAMB-231 and BT-549 cells were treated with dominant negative (dn) and constitutively
active (ca) lentivirus vectors of MEK1 and MEK5 (generous gift from Dr. Zhengui Xia).
The cells were transiently co-infected with GFP tagged dnMEK1, dnMEK5, caMEK1,
and/or caMEK5 lentivirus vectors, as indicated, for 96 hours. The morphology of infected
cells was assessed via immunostaining for the cytoskeletal protein α-actinin (Figure
4.10A). Cells that were infected with dnMEK1 or dnMEK5 alone and in combination
displayed a phenotypic shift from mesenchymal to epithelial. Transfection with caMEK1
or caMEK5 alone and in combination increased the mesenchymalization of MDA-MB-231
and BT-549 cells (Figure 4.10A, C). Infection with dnMEK5 decreased ERK5
phosphorylation by ~25% and transfection with caMEK1+caMEK5 significantly increased
ERK5 activation in MDA-MB-231 cells (Figure 4.10B). There were no significant changes
in ERK1/2 phosphorylation in MDA-MB-231 cells. In BT-549 cells, infection with dnMEK1
and dnMEK5 did not significantly decrease ERK5 or ERK1/2 phosphorylation; however,
transfection with caMEK1 or caMEK1+caMEK5 significantly increased ERK1/2 activation
in BT-549 (Figure 4.10D).
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Figure 4.10. MEK1 and MEK5 activation mediates EMT in TNBC cells. (A, B) MDA-MB-231 and (C, D) BT-549 cells were treated
with dnMEK5, dnMEK1, caMEK5, and caMEK1 alone and in combination as represented in the figure. The cells were incubated for 96
hours. Immunofluorescence staining for α-actinin was performed to assess the morphology (40X magnification). The effect on ERK1/2
and ERK5 activation was evaluated via western blotting. *p<0.05; **p<0.01 vs GFP control group determined by one-way ANOVA with
the Bonferroni post hoc test.

4.3.7 MEK1 and MEK5 pathways regulate ZEB1 expression in TNBC cells
To further understand the role MAPK pathways in the induction of MET, cellspecific responses to lentivirus-mediated MEK1/2 and MEK5 pathway inhibition and
activation on ZEB-1, a marker of mesenchymal cells, was examined. MDA-MB-231 and
BT-549 cells infected with dnMEK1, dnMEK5, caMEK1, or caMEK5 lentivirus vectors
alone and in combination were assessed for ZEB1 expression by immunofluorescence.
MDA-MB-231 cells that were infected with dnMEK1, dnMEK5, and dnMEK1+dnMEK5
vectors (GFP+ cells) had an epithelial phenotype and attenuated ZEB1 expression
(Figure 4.11A). Conversely, while cells infected with caMEK1, caMEK5, and
caMEK1+caMEK5 groups had a more pronounced mesenchymal morphology compared
to GFP control, ZEB1 expression was not increased (Figure 4.11A). BT-549 cells that
were infected with dnMEK1, dnMEK5, or dnMEK1+dnMEK5 appeared epithelial but had
no

reduction

in

ZEB1

expression

(Figure

4.11B).

caMEK1,

caMEK5,

or

caMEK1+caMEK5-infected BT-549 cells had a more pronounced mesenchymal
morphology and showed an increase in ZEB1 expression (Figure 4.11B).
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Figure 4.11 MEK1 and MEK5 activation mediates ZEB1 expression in TNBC cells. (A) MDA-MB-231 and (B) BT-549 cells were
transfected with dnMEK5, dnMEK1, caMEK5, and caMEK1 alone and in combination as represented in the figure. The cells were
incubated for 96 hours. Immunofluorescence staining for ZEB1 was performed (40X magnification).

Next, we determined if pharmacological inhibition of the MAPK pathways with
trametinib could restore the epithelial phenotype and decrease mesenchymal cell
markers following caMEK5 transfection in MDA-MB-231 and BT-549 cells. Cells were
treated with 0.1 μM trametinib in the presence of GFP or caMEK5 lentivirus to examine
the effects on cell morphology, E-cadherin, and ZEB1 expression. MDA-MB-231 cells
treated with trametinib transitioned to an epithelial phenotype and had a reduction in
ZEB1 expression (Figure 4.12) This reduction in ZEB1 was inhibited in cells that were
infected with caMEK5 (Figure 4.12).
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Figure 4.12 Effect of trametinib+caMEK5 on TNBC cell morphology and ZEB1 expression. (A, B) MDA-MB-231 and
(C, D) BT-549 cells were treated with GFP, Tra+GFP, caMEK5, and Tra+caMEK5 for 96 hours. Immunofluorescence
staining for α-actinin or ZEB1 was performed to assess MET (40X magnification).

Similar to the immunocytochemical data, caMEK5 inhibited the trametinib-mediated
decrease in ZEB1 expression as determined by western blotting in MDA-MB-231 cells
(Figure 4.13), but not in BT-549 cells (Figure 4.13). Interestingly, caMEK5 transfection
did not increase the trametinib-mediated increases in E-cadherin expression in either
TNBC cell line (Figure 4.13). Together our data suggest that targeting both ERK12 and
ERK5 pathways induces MET in MDA-MB-231 cells but targeting ERK1/2 pathway alone
induces MET in BT-549 cells as outlined in figure 4.13.
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Figure 4.13 Effect of trametinib+caMEK5 on E-cadherin and ZEB1 expression in TNBC cells. (A-D) MDA-MB-231 and
(E-H) BT-549 cells were treated/infected with GFP, Tra+GFP, caMEK5, and Tra+caMEK5 for 96 hours. Western blotting for
E-cadherin and ZEB1 expression was performed to assess MET.

4.3.8 MEK1 and/or MEK5 activation reduces the ability of trametinib to decrease
vimentin expression in MDA-MB-231 VIM RFP 2D and spheroid cell cultures.

The effect of dual ERK1/2 and ERK5 pathway inhibition on MET was found to be
most promising in MDA-MB-231 cells. Therefore, to strengthen the functional contribution
of inhibiting the ERK1/2 and ERK5 pathways in MET, MDA-MB-231 VIM RFP cells, a new
model for MET research, were infected with caMEK1 and/or caMEK5 in the presence of
DMSO, trametinib, or XMD8-92. These cells have been transformed to constitutively
express vimentin, a mesenchymal marker, via CRISPR-knock-in system and serve as a
good model to study MET (ATCC). Vimentin expression was examined in 2D and
spheroid cultures following treatment with caMEK isoforms in the presence or absence of
the MAPK inhibitors. While treatment with XMD8-92 alone did not reduce vimentin
expression in 2D cultures, treatment with trametinib moderately decreased vimentin
expression, specifically in cells that underwent a MET as determined by examining
morphology of GFP+ cells via microscopy (Figure 4.14). Treatment with caMEK1,
caMEK5, or caMEK1+caMEK5 increased vimentin expression and reduced the ability of
trametinib to decrease vimentin expression (Figure 4.14). In spheroid culture, trametinib,
but not XMD8-92, treatment reduced expression of vimentin at 96 hours, which was
rescued by transfection of caMEK1, caMEK5, or caMEK1+caMEK5 (Figure 4.14).
Spheroid viability was assessed after 7 days of treatment with inhibitors or caMEKs
(Figure 4.15). There was no baseline difference in spheroid viability after treatment with
caMEK1, caMEK5, or caMEK1+caMEK5 groups. This may indicate that the spheroidforming ability of MDA-MB-231 VIM RFP cells is at its maximum and cannot be further
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increased. XMD8-92 significantly decreased spheroid viability at 1 and 10 µM
concentrations. As expected, the reduction in spheroid viability at 1µM XMD8-92
concentration was rescued by co-treatment with caMEK5 or caMEK1+caMEK5. This
effect of caMEK5 or caMEK1+caMEK5 transfection was reversed in the presence of a
higher XMD8-92 concentration (10µM). While trametinib significantly decreased spheroid
viability at 0.1µM concentration, this decrease in viability was not reversed in the presence
of caMEK1, caMEK5, or caMEK1+caMEK5 (Figure 4.15). Pictures of vimentin-expressing
spheroids at day 0, day 7, and evidence of lentivirus infection measured by examining
GFP expression in spheroids are included in Figure 4.16.
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Figure 4.14. MEK1 and/or MEK5 activation reduces the ability of XMD8-92 or trametinib to decrease vimentin
expression in MDA-MB-231 VIM RFP cells. (A) MDA-MB-231 VIM RFP cells were treated with constitutively active
MEK1, MEK5, and MEK1+MEK5 in the presence of DMSO, XMD8-92, or trametinib for 72 hours. The cells were fixed and
stained with Hoechst. Images of Vimentin-, GFP-, and Hoechst-expressing cells were captured under 40X magnification
using EVOS microscope (n=3, most representative image shown). (B) MDA-MB-231 VIM RFP cells were treated with
constitutively active MEK1, MEK5, and MEK1+MEK5 in the presence of DMSO, XMD8-92, or trametinib for 96 hours.
Images of spheroids under transmitted light and RFP channel were captured under 4X magnification using EVOS
microscope (n=3, most representative image shown).

Figure 4.15: MEK1 and/or MEK5 activation reduces the ability of XMD8-92 or
trametinib to decrease spheroid viability in MDA-MB-231 VIM RFP cells. Spheroid
viability was assessed after 7 days of treatment with the same groups. Data indicate ±
SEM of experiments run in triplicate. ***p<0.001; ****p<0.0001 vs DMSO control group,
#p<0.05; vs individual drug+GFP determined by two-way ANOVA with the Bonferroni post
hoc test.
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Figure 4.16 Tra or XMD in the presence of constitutively active MEK1 and/or MEK5 affect spheroid viability in MDAMB-231 VIM RFP model. (A) Pictures of MDA-MB-231 VIM RFP spheroids before treatment. (B) Pictures of spheroids
after 7 days of treatment. (C) GFP expression in GFP, caMEK1, and/or caMEK5-treated spheroids.

4.3.9 Effect of dual ERK1/2 and ERK5 pathway inhibition on cell viability and
spheroid formation in breast cancer
We wanted to further characterize the effect of pharmacological inhibition of the
ERK1/2 and ERK5 pathways on cell viability and spheroid formation. Breast cancer cells
were treated with increasing concentrations of XMD8-92 and trametinib (0.1, 0.3, 1, 3 and
10 μM) alone and in combination for 72 hours (Figure 4.17). MTT assay was performed
to evaluate cell viability. While trametinib and XMD8-92 alone decreased cell viability in
MDA-MB-231 and TU-BcX-4IC cells, there was no synergy in combination groups. In BT549 cells, there was a reduction in cell viability after treatment with XMD8-92, but not
trametinib. In TAMR MCF-7 cells, the combination of XMD8-92 and trametinib
synergistically reduced cell viability.
EMT is known to promote anchorage-independent growth.97,
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We found that

trametinib alone significantly decreased cell viability and/or spheroid viability in all breast
cancer models and its effects were most pronounced in MDA-MB-231 cells (Figure 4.18)
At the 10uM concentration, XMD8-92 decreased spheroid viability in MDA-MB-231 and
TU-BcX-4lC cells, but not BT-549 or TAMR cells. The reduction in spheroid viability in
response to trametinib was greater in MDA-MB-231 cells (~90%) compared to BT-549
(~40%), TU-BcX-4IC (~35%), or TAMR-MCF-7 cells (~40%). These data suggest that
while ERK1/2 and ERK5 inhibition is sufficient to target MDA-MB-231 and TAMR MCF-7
cells, alternative pathways may be important to further reduce spheroid viability in BT549 and TU-BcX-4IC cells. The combination of Tra+XMD at the 0.1 and 1uM
concentrations, synergistically inhibited spheroid viability in TAMR MCF-7 cells, but not
the TNBC cells. (Figure 4.18). Overall, these findings suggest that dual ERK1/2 and ERK5
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inhibition is a relevant strategy to target tamoxifen-resistant breast cancer cells.
Additional alternative pathways that may mediate survival in TNBC cells will be discussed
in

chapter

5.

Figure 4.17: Effect of XMD8-92 and trametinib alone and in combination on breast cancer
cell viability. Effect of simultaneous treatment with XMD8-92 and trametinib was evaluated
compared to XMD and trametinib alone. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs
trametinib; ##p<0.01; ###p<0.001; ####p<0.0001 vs XMD8-92 as determined by two-way
ANOVA with the Bonferroni post hoc test.
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Figure 4.18. Effect of ERK1/2 and ERK5 inhibition alone and together on spheroid viability in diverse breast cancer subtypes.
The cells were treated with increasing concentrations of XMD8-92 and/or trametinib for 7 days. Pictures of spheroids were obtained
before treatment and 7 days after treatment (4X magnification) (A) MDA-MB-231, (B) BT-549, and (C) TU-BcX-4IC, and (D) TAMR
MCF-7 cells. Data indicate ± SEM of experiments run in triplicate *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control group,
####p<0.0001 vs individual drug determined by one-way ANOVA with the Bonferroni post hoc test.
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4.4 Discussion
Mesenchymal cancer cells are migratory and invasive, leading to metastases.
There are currently no effective treatments for metastasis. Interestingly, activation of the
ERK1/2 and ERK5 signaling pathways leads to an epithelial to mesenchymal transition
(EMT) and poor patient survival in several cancers, including TNBC and endocrineresistant breast cancers.16, 23, 30, 102-104, 115-117 Genomics data from our research indicate
that MAPK3 (ERK2) and MAPK7 (ERK5) gene expression significantly correlated with the
mesenchymal markers VIM or ZEB1, but not with the epithelial marker CDH1 (Figure 4.1A
and C). MAPK1 (ERK1) positively correlated with mesenchymal markers VIM and ZEB1
and epithelial marker CDH1 (E-cadherin), indicating that MAPK1 may mediate an
intermediate epithelial/mesenchymal state where both epithelial and mesenchymal
markers are co-expressed (Figure 4.1B). These data support a role for ERK1/2 and ERK5
signaling in EMT in TNBC. However, the relative roles of these pathways in inducing MET,
a reversal of the EMT, in these cancers is unknown. Understanding of EMT and response
to therapy is further complicated due to crosstalk between the ERK1/2 and ERK5
pathways and different functions of ERK5 in the nucleus versus the cytosol. To our
knowledge, this is the first study to examine the independent and overlapping roles of the
ERK1/2 and ERK5 signaling cascades on MET, nuclear localization of ERK5, cell
migration, proliferation, and spheroid formation in TNBC and TAMR breast cancer.
In the current study, trametinib, a clinically relevant MEK1/2 inhibitor, and XMD892, an ERK5 inhibitor, induced a MET in MDA-MB-231 TNBC cells as shown by
morphological characteristics, increased expression of E-cadherin, and/or decreased
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expression of ZEB1 (Figure 4.3A). In MDA-MB-231, BT-549, TU-BcX-4IC, and TAMR
MCF-7 cells, treatment with trametinib resulted in an epithelial-like morphology (Figure
4.3B-D). However, the morphological changes induced by trametinib in BT-549 cells were
less pronounced than those in MDA-MB-231 cells. This could be due to inhibition of both
ERK1/2 and ERK5 pathways, a subsequent increase in E-cadherin, and decrease in
ZEB1 expression by trametinib in MDA-MB-231 cells, but not in BT-549 cells. XMD8-92
treatment only induced an epithelial morphology MDA-MB-231 cells. Interestingly, the
morphological changes induced by trametinib in the MDA-MB-231 cells were more
pronounced than those induced by XMD8-92. Again, this may be because trametinib
inhibited both ERK pathways and altered expression of cell markers in favor of an
epithelial phenotype (increased E-cadherin; decreased ZEB1), while XMD8-92 only
inhibited the ERK5 pathway and reduced only ZEB1 expression in MDA-MB-231 cells.
Overall, these data suggest that inhibition of ERK1/2 or ERK5 activity is sufficient to
induce an MET in MDA-MB-231 cells, while inhibition of both ERK1/2 and ERK5 pathways
may be necessary to induce a full MET. Conversely, in BT-549, TU-BcX-4IC, and TAMR
MCF-7 cells, inhibition of the ERK1/2 pathway may be sufficient to induce an MET.
Additionally, as trametinib consistently increased E-cadherin in TNBC and TAMR breast
cancer models, E-cadherin may be used as a potential biomarker to predict MET induced
by trametinib treatment in metastatic cancers.
Consistent with the effect on MET, trametinib decreased cell migration in TNBC
and TAMR MCF-7 cells, suggesting that ERK1/2 inhibition is sufficient to decrease cell
migration in these cells. At 10 μM concentration, XMD8-92 decreased cell migration only
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in MDA-MB-231 cells. Again, these data are consistent with the induction of MET
following XMD8-92 treatment in MDA-MB-231 cells and suggest that ERK5 pathway
inhibition is also sufficient to decrease cell migration in MDA-MB-231 cells.
ERK1/2 and ERK5 activation are known to mediate cell proliferation by mediating
G1-S transition during the cell cycle via distinct effects on cyclinD1 expression and
activation.118 Trametinib decreased cell proliferation by 80% in TAMR MCF-7 cells.
However, in MDA-MB-231 cells, trametinib only decreased cell proliferation by ~50%.
These findings suggest that alternative pathways may mediate cell proliferation in these
cells. The effect of XMD8-92 on cell proliferation was evident only at the highest dose (10
μM) in MDA-MB-231 and TAMR MCF-7 cells. We have previously shown that effects of
a high XMD8-92 dose could be recapitulated by the addition of AX15836 (ERK5 inhibitor)
and CPI203 (BRD4 inhibitor).37 Therefore, at high doses, in addition to ERK5 inhibition,
XMD8-92 may have off-target effects, including inhibition of bromodomain (BRD)4. 119
Trametinib or XMD8-92 did not decrease cell proliferation in BT-549 cells, which may
indicate that alternative pathways mediate cell proliferation in these cells. XMD8-92
significantly decreased cell proliferation at 10 μM concentration, while trametinib did not
decrease cell proliferation in TU-BcX-4IC cells. As indicated above, BT-549 cells are
PTEN mutant cells and may rely more on the AKT pathway for survival and proliferation.
Additionally, together with the data on cell migration, these data suggest that migration
and proliferation may be controlled by distinct mechanism in TNBC cells.
We observed that MDA-MB-231 cells were the most responsive to the effects of
XMD8-92 and trametinib on MET, whereas BT-549 cells were the least responsive, which
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led us to characterize differences in cellular signaling between the two TNBC models. To
explore these putative differences in the MAPK signaling pathways, we first examined the
effects of trametinib and XMD8-92 on nuclear localization of ERK5. Our is the first study
to examine nuclear localization of ERK5 in TNBC.
We found that the ERK5 inhibitor did not decrease nuclear ERK5 activation or total
expression. This observation is consistent with a recent study, which has shown that
ERK5 inhibitors that target the kinase domain were shown to activate the transcriptional
activation domain (TAD) of ERK5, resulting in the nuclear localization and increased
transcriptional activity of ERK5.120 This may explain why our data with respect to the effect
of ERK5 inhibition on E-cadherin conflicts with studies that have shown that inhibition of
ERK5 via knockdown or knockout enhances E-cadherin expression in several cancer
models.121-122 Since trametinib decreased nuclear ERK5, ERK1/2 activation may be a
putative mechanism for the translocation of ERK5 into the nucleus in MDA-MB-231 cells.
ERK1/2 has been shown previously to promote ERK5 translocation to the nucleus in
response to growth factor stimulation.59 However, constitutively active RAF may be
responsible for constitutive ERK1/2 activation and subsequent translocation of ERK5 in
the nucleus of MDA-MB-231 cells under unstimulated condition. We are currently
investigating mechanisms for ERK5 nuclear translocation in BT-549 cells.
To further explore hypothesis that inhibition of both the ERK1/2 and ERK5
pathways are necessary to induce the MET in TNBC, MDA-MB-231 and BT-549 cells
were infected with dominant negative (dn) and constitutive active (ca) MEK1 and/or
MEK5. Although phenotypic shifts were noted following infection of the ca or dn MEK,
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the morphological transitions were more pronounced when both pathways were activated
or inhibited in MDA-MB-231 and BT-549 cells. This was supported by decrease in ZEB1
expression in MDA-MB-231 cells following dnMEK1 and/or dnMEK5 infection and
increase in ZEB1 expression in BT-549 cells following caMEK1 and/or caMEK5 infection
(Figure 4.12). It is possible that ZEB1 expression is maximum in MDA-MB-231 cells and
could not be induced further. Therefore, the more pronounced mesenchymal morphology
following caMEK5 and caMEK1+caMEK5 infection may be a result of increase in vimentin
expression (Figure 4.14) and/or ERK5 activation (Figure 4.10B) and its association with
the actin cytoskeleton as previously described.108 Moreover, ERK5 activation increased
more significantly in caMEK1 + caMEK5 group vs GFP than in the caMEK5 group vs GFP
(Figure 4.10B), indicating that ERK5 may be activated by both MEK1 and MEK5 signaling.
This observation supports the data that show that trametinib, a known MEK1/2 inhibitor,
decreased ERK5 activation in MDA-MB-231 cells. We speculate that the effect of
trametinib on ERK5 inhibition was mediated via MEK1/2 inhibition and not by direct
binding of trametinib to MEK5 or ERK5. Since ERK1/2 and ERK5 share 50% sequence
homology at the N-terminal domain, it is possible that MEK1/2 may phosphorylate ERK5
by direct binding. It is also possible that ERK1/2 may phosphorylate ERK5 at its Cterminal by direct interaction, as reported previously.59 These data further support the
conclusion that inhibition or activation of both pathways is necessary for the MET or EMT,
respectively. These data, together with the effect of trametinib and XMD8-92 on
morphology, suggest that inhibition of both the ERK1/2 and ERK5 pathways is necessary
to induce a full MET in TNBC cells.
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The trametinib-mediated decrease in ZEB1 expression was partially reversed in
MDA-MB-231 cells transfection with caMEK5. These data suggest that trametinib
mediates its effect on MET in MDA-MB-231 cells, at least in part, via ERK5 inhibition and,
most likely, via dual ERK1/2 and ERK5 inhibition. However, the trametinib-mediated
increase in E-cadherin expression was not decreased by caMEK5, which may indicate
that trametinib induces E-cadherin expression via ERK1/2 inhibition alone in these TNBC
cells. This observation further supports the data that suggest there is no change in Ecadherin expression following XMD8-92 treatment in MDA-MB-231 cells.
While trametinib caused an overall decrease in ZEB1 expression in BT-549 cells,
transfection with caMEK5 did not decrease its ability to induce MET as determined by
examining cell morphology, E-cadherin, expression, and ZEB1 expression. This further
supports our data that suggest that ERK1/2 inhibition, but not ERK5 inhibition, induces
MET in BT-549 cells. We also observed that there was an overall reduction in ZEB1
expression in cells with an epithelial morphology following treatment with trametinib in
both the TNBC cell lines and there was no cell population that had a complete loss of
ZEB1. Such fine-tuning could be advantageous to avoid catastrophic side effects on
healthy mesenchymal cells in the body, which depend on ZEB1 for their normal function.
The effect of ERK1/2 and ERK5 pathway inhibition or activation on vimentin
expression were examined in 2D and spheroid cultures of MDA-MB-231 cells. Trametinib
moderately decreased vimentin expression in MDA-MB-231 VIM RFP cells in 2D culture
(Figure 4.14A), but completely inhibited vimentin expression in spheroid culture (Figure
4.14B), indicating that treatment with trametinib may be specifically important in targeting
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mesenchymal and anoikis-resistant cells. Moreover, trametinib-mediated decrease in
spheroid viability was not rescued by caMEK1, caMEK5, and caMEK1+caMEK5 groups
at 7 day (Figure 4.15). This indicates that the reduction in vimentin expression in
spheroids was not due to a decrease in spheroid viability. Since the reduction of vimentin
by trametinib was partially reversed by co-treatment with constitutively active MEK1
and/or MEK5, trametinib-mediated decrease in vimentin may be due to inhibition of both
ERK1/2 and ERK5 pathways in MDA-MB-231 cells. XMD8-92 significantly decreased the
spheroid viability at 1µM concentration, which was rescued by caMEK5 and
caMEK1+caMEK5 transfection indicating that ERK5 has a crucial role in regulating the
survival of anoikis-resistant spheroids (Figure 4.15). Dysregulation of anoikis, a type of
programmed cell death that occurs in cells when they detach from a cellular matrix, is an
important step in tumor metastases. Together, these data suggest that ERK1/2 activation
has a greater role in regulating the EMT in spheroids, while ERK5 activation regulates the
survival of these anoikis-resistant spheroids.
As previously described, some single-agent inhibitors of MAPK pathway(s) led to
an intermediate E/M state, which may be a predictor of metastases and poor prognosis.
Therefore, combination strategy for MAPK inhibitors needs to be developed. We
examined the effect of dual ERK1/2 and ERK5 pathway inhibition on spheroid viability,
an assay representative of EMT. MAPK gene alterations are common in endocrineresistant breast cancer.123 This explains why Tra and XMD combination produced greater
inhibition of spheroid and cell viability compared to either drug alone in TAMR MCF-7
cells (Figure 4.17-4.18). In conclusion, our data suggest crucial roles of ERK1/2 and
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ERK5 pathways in mediating EMT and MET, cell migration, proliferation, and spheroid
formation in TNBC and TAMR breast cancer. Since crosstalk may exist between the
MAPK and PI3K or epigenetic pathways, in the next chapter, we will discuss some
relevant combination strategies of MAPK pathway inhibitors with AKT or epigenetic
inhibitors.
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Chapter 5: Effect of Compound 1 (SC-1-151) alone and in combination with
epigenetic inhibitors, CDK4/6 inhibitor Palbociclib, or AKT inhibitor ipatasertib on
cell viability, proliferation, or spheroid formation in breast cancer
5.1 Introduction
The use of MEK1/2 inhibitors as cancer therapeutics has been clinically beneficial
for treatment of previously incurable cancers, such as melanomas. However, the
therapeutic use of MEK1/2 inhibitors is limited due to dose-dependent side effects and
drug resistance. Therefore, several components, including activation mechanisms,
kinase-substrate relationships, feedback mechanisms, and crosstalk with parallel
pathways, need to be examined.
We have shown that the novel dual MEK1/2 and MEK5 inhibitor, compound 1 (SC1-151; compound 1 will be referred to as SC-1-151 from here on) decreases cell
proliferation, migration, and spheroid formation in the previous chapter. However,
sustained inhibition of the MAPK pathway can result in the loss of negative feedbackmediated inactivation loops and paradoxical activation of ERK. 124 This could be mediated
via a decreased expression of tumor suppressor dual specificity phosphatase (DUSP) 6,
which is transcriptionally regulated by members of the Erythroblast Transformation
Specific (ETS) family of transcription factors.125 Reactivation of RNA polymerase-IImediated parallel survival pathway transcription factors, such as ETS1, ETS2, and
bromodomain 4 (BRD4), have been shown to compensate for the inhibition of the MAPK
pathway, limiting the standalone targeting of MAPKs (Figure 5.1). In fact, BRD4 is known
to promote breast cancer metastasis via Jagged1/Notch1 signaling.126 Therefore, the
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combination of MAPK inhibitors with transcription factor-targeted small molecule
inhibitors, such as JQ-1 (pan-BRD inhibitor), is a relevant strategy for the treatment of
breast cancer tumorigenesis. Histone deacetylases (HDACs) are another class of
epigenetic regulators that are also known to mediate resistance to MAPK inhibitors in
melanoma and prostate cancer.127-128 Therefore, we hypothesized that SC-1-151+LBH589 (HDAC inhibitor) will synergize to reduce cell viability in triple-negative and TAMR
breast cancers.

Figure 5.1: Negative feedback regulation of RAS/MAPK pathway.129
Dysregulation of the cell cycle often accompanies the dysregulation of the MAPK
pathways, either as a direct consequence of aberrant MAPK activation (or vice versa) or
as parallel pathways that promote tumorigenesis (Figure 5.2).20,
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Cyclin-dependent

kinase 4/6 (CDK4/6) phosphorylates retinoblastoma (Rb) and promotes entry into the cell
cycle by mediating transition into the synthesis (S) phase of the cell cycle. CDK4/6
102

inhibitors block Rb phosphorylation and lead to cell cycle arrest. Palbociclib, an oral and
selective CDK4/6 inhibitor, is FDA approved for use in the first- and second-line settings
for metastatic hormone-receptor positive breast cancer. Moreover, CDK4/6 inhibitors in
combination with MAPK inhibitors decrease cell proliferation in melanoma, head and neck
cancer, and colorectal cancer.131 However, the effect of CDK4/6 inhibitors in combination
with MAPK inhibitors at low concentration in tamoxifen-resistant breast cancer remains
unknown. As crosstalk between the ERK and AKT signaling pathways has been noted in
TNBC,37 the AKT pathway may lead to reduced efficacy of MAPK inhibitors in TNBC.
Therefore, the effect of MAPK pathway inhibition in combination with AKT inhibition was
evaluated on spheroid viability in TNBC and TAMR MCF-7 cells.
In this chapter, we explore three strategies to improve the efficacy SC-1-151. First,
we examine the effect of cotreatment with inhibitors of MAPK signaling and
bromodomains or HDAC on cell viability in TNBC and TAMR cells using SC-1-151 in
combination with JQ-1. Next, we evaluate the effect of SC-1-151 in combination with
palbociclib on cell proliferation in TAMR breast cancer cells. Finally, SC-1-151 or the
MEK5 inhibitor SC-1-181 was used in combination with the AKT inhibitor ipatasertib to
evaluate the effect of combination on spheroid viability. Overall, these strategies may help
decrease rate of recurrence due to drug resistance and prevent dose-limiting toxicities.
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Figure 5.2: ERK5, ERK1/2, and CDK4/6 pathways and the cell cycle. ERK1/2 and
ERK5 pathways may regulate the cell cycle and proliferation via CD1 and CDK4/6.
5.2 Hypothesis
SC-1-151 and epigenetic, CDK4/6, or AKT inhibitors will produce a synergistic decrease
in cell viability in triple-negative and tamoxifen-resistant breast cancer cells.
5.3 Results
5.3.1 Effect of Compound 1 (SC-1-151) on cell viability in breast cancer.
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Figure 5.3: Effect of SC-1-151 on breast cancer cell viability. Cells were treated with
SC-1-151 at increasing concentrations for 72 hours. MTT assay was performed to assess
cell viability.
TNBC and TAMR breast cancer cell lines were treated with SC-1-151 at increasing
concentrations (0.01, 0.03, 0.1, 0.3, 1, 3, 10 uM) for 72 hours. MTT assay was performed
to assess cell viability. SC-1-151 decreased cell viability at 0.01 – 10uM concentrations
in MDA-MB-231 cells, but not in BT-549 cells or in ERK5 knockout (KO) MDA-MB-231
cells. SC-1-151 was equally effective in reducing cell viability in wildtype and tamoxifenresistant MCF-7 cells (Figure 5.3).
5.3.2 SC-1-151 synergistically inhibits cell viability in combination with JQ-1 in
breast cancer
Since sustained MAPK inhibition may result in a loss of feedback mediated via
DUSP6, it is important to investigate the effect of MEK inhibitors in combination with
alternative therapies. Since alternative pathways, including BRD4 or HDAC signaling,
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could promote cell survival in the absence of MEK1/2 signaling, we combined SC-1-151
with bromodomain inhibitor JQ-1 or HDAC inhibitor LBH589. SC-1-151 and JQ-1 were
found to synergistically decrease cell viability in TNBC and TAMR cells at low
concentrations. There was a greater that 50% reduction in cell viability after treatment of
TNBC cells with 0.3 uM concentration of each inhibitor and TAMR cells with 0.1 uM of
each inhibitor as indicated by the fraction affected (Figure 5.4, Table 5.1).
The crosstalk between RAS and PI3K pathways is well-defined in cancer.132
Interestingly, we have noted an increase in AKT activation following treatment with SC1-151. Others have reported that JQ-1 decreases AKT activation in endometrial cancer
via upregulation of PTEN.133 Therefore, to gain mechanistic insights behind the observed
synergy between SC-1-151 and JQ-1, ERK1/2 and AKT activation was examined after 5
days of treatment with SC-1-151 or JQ-1 alone and in combination. SC-1-151, but not
JQ-1, inhibited ERK1/2 phosphorylation, however, the combination of SC-1-151 and JQ1 produced a greater inhibition of ERK1/2 phosphorylation than SC-1-151 alone. A
compensatory increase in AKT phosphorylation was noted following SC-1-151 treatment.
While JQ-1 did not decrease AKT activity alone, it inhibited the increase in AKT activation
by SC-1-151 (Figure 5.5).
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Figure 5.4: SC-1-151 + JQ-1 combination synergistically decreases cell viability in
diverse breast cancer subtypes. (A) MDA-MB-231, (B) BT-549, (C) MCF-7 TAMR cells
were treated with drugs alone and in combination for 72 hours. Cell viability was
determined using MTT assay.

107

108

Table 5.1: Effect of SC-1-151 and JQ-1 combination on fraction affected and
combination index. The fraction affected was calculated and synergy was determined
by Chou-Talalay Method using CompuSyn Software.
5.3.3 Effect of SC-1-151 and JQ-1 alone and in combination on ERK1/2 and AKT
activation.

Figure 5.5: JQ-1 decreases AKT activation induced by SC-1-151 treatment in MDAMB-231 cells. MDA-MB-231 cells were treated with 1 μM SC-1-151 and 300 nM JQ-1
alone and in combination for 5 days. ERK1/2 and AKT activation was examined by
western blotting. Data were analyzed by One-way ANOVA with Bonferroni post-hoc
correction.
109

5.3.4 SC-1-151 and LBH-589 cotreatment does not synergistically reduce cell
viability in TNBC and TAMR MCF-7 cells.
MDA-MB-231, BT-549, and TAMR MCF-7 cells were treated with increasing
concentrations of SC-1-151, LBH-589, and 1:1 combination of the two drugs for 72 hours.
Our data suggest that LBH-589 or SC-1-151 treatment alone inhibited cell viability in
breast cancer cell lines. SC-1-151+LBH-589 cotreatment did not produce a synergistic
reduction in cell viability in TNBC cells (Figure 5.6). The lack of synergy may be due to a
maximal decrease in cell viability following LBH-589 treatment alone.
We also examined ERK1/2 and AKT activation after treatment with 100nM LBH589 or 1 μM SC-1-151 alone and in combination. LBH-589 produced a compensatory
increase in ERK1/2 activation. This increase in ERK1/2 activation was inhibited by SC-1151. Both SC-1-151 and LBH-589 treatment alone produced a 10-fold increase in AKT
activation, which may explain why there was no synergy with this combination (Figure
5.7).
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Figure 5.6: SC-1-151 + LBH589 modestly synergize to decrease cell viability in BT549 cells. (A) MDA-MB-231, (B) BT-549, (C) MCF-7 TAMR cells were treated with drugs
alone and in combination for 72 hours. Cell viability was determined using MTT assay.
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Figure 5.7: SC-1-151 and LBH-589 activate AKT in MDA-MB-231 cells. MDA-MB-231
cells were treated with SC-1-151 and LBH-589 alone and together to examine kinase
activation after 5 days of treatment.
5.3.5 Effect of SC-1-151+Palbociclib on cell proliferation in TAMR MCF-7 cells.
Recent studies have shown that MEK inhibition is important for enhanced efficacy
of CDK4/6 inhibitors in various cancer models.131 TAMR MCF-7 cells were treated with
SC-1-151 and palbociclib alone and in combination at 0.1 or 1 µM concentration.
Palbociclib significantly decreased cell proliferation at 0.1 and 1 µM concentrations, while
SC-1-151 decreased cell proliferation only at the 1 µM concentration. In the combination
groups, the decrease in cell proliferation was mainly mediated by palbociclib (Figure 5.8).
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Figure 5.8: Effect of SC-1-151 in combination with Palbociclib on cell proliferation
in TAMR MCF-7 cells.
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Since the reduction in cell proliferation in 1:1 SC-1-151:Palb combination groups
was dominated by palb, we examined the effect of a larger ratio of SC-1-151 to Palbociclib
(10:1 combination ratio). SC-1-151 (1uM) and Palbociclib (0.1uM) synergistically
decreased cell proliferation in wildtype MCF-7 cells (Figure 5.9A); however, the reduction
in cell proliferation in TAMR MCF-7 cells was mainly mediated by SC-1-151. While
Palbociclib alone significantly decreased cell proliferation, there was no further reduction
in the combination group (Figure 5.9 B).
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Figure 5.9: SC-1-151 and Palbociclib synergistically decrease cell proliferation in
(A) WT-MCF-7 cells but not in (B) TAMR-MCF-7 cells.
5.3.6 Inhibition of MEK1/2, MEK5, and PI3K pathways decreases nuclear ERK5
expression or activation and decreases spheroid viability in breast cancer cells.
Treatment with the AKT inhibitor ipatasertib alone, did not decrease spheroid
viability in MDA-MB-231 and TAMR MCF-7 cells. However, the effect of ipatasertib on
cell viability was potentiated by MEK inhibitors in these cells (Figure 5.10 A, C). Ipatasertib
alone decreased spheroid formation in BT-549 and TU-BcX-4IC cells and there was a
synergistic effect when these cells were treated with ipatasertib in combination with the
MEK inhibitors (Figure 5.10B, D).
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Figure 5.10: Effect of SC-1-151 or SC-1-181 in combination with ipatasertib on spheroid viability in diverse breast
cancer subtypes. Effect of SC-1-151 (dual MEK1/2 and MEK5 inhibitor) or SC-1-181 (MEK5 inhibitor) alone and in
combination with ipatasertib was evaluated on spheroid viability in (E) MDA-MB-231, (F) BT-549, (G) TU-BcX-4IC and (H)
TAMR MCF-7 cells. Spheroid viability was assessed on day 7 after treatment. Data indicate ± SEM of experiments run in
triplicate *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs DMSO control group, ##p<0.01; ###p<0.001; ####p<0.0001 vs
individual drug determined by one-way ANOVA with the Bonferroni post hoc test.

Our findings suggest that alternative mechanisms may underlie the activation and
nuclear translocation of ERK5 in BT-549 cells because treatment with ERK5 inhibitor
XMD8-92 or MEK1/2 inhibitor trametinib did not decrease nuclear ERK5 activation in BT549 cells. This may also explain why trametinib only induced a partial MET and XMD did
not induce a MET in BT-549 cells. We hypothesized that nuclear ERK5 may be
responsible for increasing the transcription of genes involved in EMT and spheroid
formation. To understand the differences in response to Ipat+181 or Ipat+151 treatment
in different breast cancer subtypes, MDA-MB-231 (responsive to MEK1/2 and MEK5
inhibition) and BT-549 cells (responsive to MEK1/2, MEK5, and AKT inhibition) were
treated with ipatasertib alone and in combination with SC-1-181 or SC-1-151 for 72 hours
and nuclear extracts were collected to examine ERK5 activity and expression of a MEF2
family member MEF2C, a downstream target of ERK5 signaling. MEF2C levels in the
nucleus are representative of ERK5 activity.134
In MDA-MB-231 cells, SC-1-151, like trametinib (Chapter 4), decreased nuclear
ERK5. SC-1-151 and Ipat+SC-1-151 combination groups produced a maximum decrease
in nuclear ERK5 and MEF2C expression. SC-1-181 or Ipatasertib alone or in combination
did not decrease nuclear ERK5 activation, expression. Ipat+SC-1-151 group produced a
maximum decrease in MEF2C expression (Figure 5.11A). In BT-549 cells, ipatasertib
modestly decreased ERK5 activation and SC-1-181 modestly decreased MEF2C
expression. Surprisingly, ipatasertib in combination with SC-1-181 or SC-1-151 produced
a maximum decrease in nuclear ERK5 and MEF2C expression (Figure 5.11B).
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Figure 5.11: Inhibition of MAPK and PI3K pathways decreases nuclear ERK5 and
MEF2C in TNBC cells. (A) MDA-MB-231 (B) BT-549 cells were treated with AKT inhibitor
ipatasertib alone and in combination with SC-1-181 of SC-1-151 for 72 hours. Nuclear
extracts were prepared as per the standard protocol.
5.4 Discussion:
In this chapter, we further characterized the effects of SC1-151 on TNBC and
TAMR viability, examined the effects of SC-1-151 alone and in combination with a BRD4,
HDAC, or cell cycle inhibitor on breast cancer cell viability and proliferation, and examined
the effect of the inhibitors on ERK1/2 and AKT pathway activation. SC-1-151 decreased
cell viability in MDA-MB-231, TAMR MCF-7, and WT MCF-7 cells. In contrast, SC-1-151
did not decrease cell viability in BT-549. MDA-MB-231 cells have a mutation in the RAF
gene which leads to aberrant MEK activity. This may explain why these cells were more
sensitive than BT-549 cells to the toxic effects of the dual ERK1/2 and ERK5 pathway
inhibitor SC-1-151. The decrease in cell viability following SC-1-151 treatment in wildtype
and TAMR MCF-7 cells suggests that tamoxifen-resistance does not affect the cell
viability response to dual MEK1/2 and MEK5 inhibition. SC-1-151 did not inhibit cell
viability in ERK5-KO MDA-MB-231 cell. This may indicate that inhibition either ERK1/2 or
ERK5 pathway may be sufficient to decrease cell viability in MDA-MB-231 cells and
perhaps ERK1/2 does not fully compensate for the loss of ERK5 in MDA-MB-231 cells.
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In the current study, inhibition of MEK1/2/5 and BRD4 with SC-1-151 and JQ-1,
respectively, produces a synergistic effect on cell viability in TNBC and TAMR breast
cancer cells. This synergy may be a result of inhibition of shared downstream targets.
ETS1/2 is an important downstream target of the ERK1/2 pathway. ETS1/2-mediated
gene transcription is also mediated by bromodomain 4 (Figure 5.12). Moreover, we found
that a compensatory increase in AKT activation by SC-1-151 was inhibited by JQ-1, which
may also explain the observed synergy. Although pharmacological inhibitors with dual
ERK5/BRD4 activity are known to decrease cell proliferation in cancer, ours is the first
study to report a synergistic effect on cell viability with inhibition of the ERK5 and BRD4
pathways.119
The effects of histone deacetylase inhibitors on tumor progression are being
recently studied in metastatic breast cancers.135 Phase-III clinical trial with HDACi in
breast cancer has shown promising results. HDAC inhibitors have been shown to
synergize

with

MAPK

inhibitors

to

inhibit

cell

viability

and

stemness

in

medulloblastomas.136 However, we did not observe synergy between MAPK and HDAC
inhibitors in TNBC and TAMR breast cancer. The increase in AKT activation by SC-1-151
(dual MEK1/2 and MEK5 inhibitor) and LBH-589 may be responsible for lack of synergistic
response in the combination group. LBH-589 (HDAC inhibitor) alone may have decreased
cell viability to its maximum. In future, more combination ratios will be utilized to evaluate
the effect on cell viability as well as other functional assays representative of EMT. MDAMB-231 cells have a mutation in the RAF gene which leads to aberrant MAPK activity.
This may explain why these cells were more sensitive to the toxic effects of the dual
ERK1/2 and ERK5 pathway inhibitor SC-1-151. Overall, the results from our study
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highlights the relevance of targeting MAPK pathway in combination with BET or HDAC
inhibitors to target cell viability and proliferation in breast cancer.

Figure 5.12: Coregulation of ETS1/2-mediated response by MEK1/2 and
bromodomain pathways.129

Cyclin-dependent kinases play a critical role in regulating the cell cycle and are
relevant targets in cancer. Activation of cyclinD1 levels by upstream mitogenic factors and
activation of RAS-RAF-MEK-ERK can promote cellular progression to the S phase and
compensate for inhibition of the cell cycle by CDK4/6 inhibitors.130 To explore a possible
synergistic effect of MAPK and cell cycle inhibition, we examined proliferation in WT and
TAMR MCF-7 cells following treatment with SC-1-151 or Palbociclib, the CDK4/6 inhibitor,
alone and in combination. In the SC-1-151 and palbociclib combination, the reduction in
cell proliferation was mediated by either palbociclib in 1:1 combination or SC-1-151 in
10:1 combination group. Future studies will be performed to utilize more combination
ratios and to examine synergy.
We found that dual ERK1/2 and ERK5 inhibition was sufficient to inhibit spheroid
viability in MDA-MB-231 and TAMR MCF-7 cells but further inhibition of AKT was
necessary further inhibit spheroid formation in BT-549 and TU-BcX-4IC cells. This
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difference may be because SC-1-151, inhibits both ERK1/2 and ERK5 activation by EGF
in MDA-MB-231 and TAMR MCF-7 cells, but only inhibits the ERK1/2 activation in BT549 cells. We found that dual ERK1/2 and ERK5 inhibition was sufficient to decrease
spheroid formation in MDA-MB-231 and TAMR-MCF-7 cells whereas additional inhibition
of AKT was necessary further inhibit spheroid formation in BT-549 and TU-BcX-4IC cells.
As discussed in the previous chapter, trametinib, a MEK1/2 inhibitor or XMD8-92,
an ERK5 inhibitor did not reduce nuclear ERK5 in BT-549 cells meaning alternative
pathways may regulate ERK5 nuclear localization in BT-549 cells. Since crosstalk
between ERK5 and AKT pathways has been noted and BT-549 cells have a PTEN
mutation, we examined whether inhibition of AKT would reduce nuclear ERK5 activity.
ERK5 activation and MEF2C expression were examined after treating MDA-MB-231 and
BT-549 cells with ipatasertib alone and in combination with SC-1-181 or SC-1-151.
Overall, our data suggest that MEK1/2, MEK5, and AKT pathways play an important role
in regulating nuclear ERK5 activity. Decrease in nuclear ERK5 activity may be one of the
reasons behind observed synergy between MAPK and AKT inhibitors.
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Chapter 6: Effect of MAPK or PI3K pathway inhibition on low-dose
chemotherapeutic sensitivity in triple-negative breast cancer
6.1 Introduction
Doxorubicin, paclitaxel, and carboplatin are the chemotherapeutic drugs that
remain the mainstay treatment for TNBC patients.137 Unfortunately, TNBCs become
resistant to most chemotherapeutic drugs. Drug resistance and off-target toxicity are
major problems associated with administration of high doses of chemotherapeutic agents
in the clinic. Inherent and acquired mechanisms of drug resistance include dependence
of tumors on alternative/novel mutations, increase in drug efflux transporters, and
compensatory activation of kinase pathways, which can prolong the survival of cancer
cells.
ERK5 overexpression is associated with poor overall survival in breast cancer
patients after treatment with chemotherapeutic drugs (Figure 6.1).30 ERK5 inhibition is
known to reverse doxorubicin resistance via p53 upregulation in lung and ovarian
cancers.138 AKT activation is known to mediate resistance to doxorubicin by
downregulated

PTEN

expression

in

ER-positive

downregulation of ETS-1, a target of ERK1/2

breast

cancer.139

Moreover,

was found to enhance cisplatin and

doxorubicin toxicity in breast cancer. 18 In ovarian cancer, ERK1/2 activation following
cisplatin treatment has been shown to mediate resistance to cisplatin.140 Moreover,
ERK1/2 and AKT pathways are known to mediate chemoresistance in cancer via
upregulation of multi-drug transporter proteins.141-142 The goal of this research is to
examine the effects of chemotherapeutic drugs at low doses on kinase activation and cell
124

viability in combination with known MAPK pathway inhibitors XMD8-92, trametinib, and
ipatasertib.

Figure 6.1: Poor overall survival after systemic treatment is associated with MEK5ERK5 overexpression in TNBC patients.30
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6.2 Hypothesis
Chemotherapeutic drugs will enhance sensitivity of MAPK or PI3K pathway inhibitors at
low doses in triple-negative breast cancer cells.
6.3 Results
6.3.1 Effect of chemotherapeutic drugs doxorubicin, paclitaxel, and carboplatin on
cell viability in TNBC
Concentration-response studies revealed differential responses of MDA-MB-231
and BT-549 cells to different chemotherapeutic drugs (Figure 6.2). These studies were
performed to identify low doses at which the chemotherapeutic drug produced no effect
on cell viability. Cells are resistant to the toxic effects of the drugs at low doses and the
goal of our research is to examine whether combination of low-dose kinase inhibitors with
low-dose chemotherapeutic drugs synergistically inhibit cell viability.
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Figure 6.2: Cell viability response to doxorubicin, paclitaxel, and carboplatin in (AC) MDA-MB-231 and (D-F) BT-549 cells.
Drug

MDA-MB-231

BT-549

Doxorubicin

100 nM

10 nM

Paclitaxel

100 pM

100 pM

Carboplatin

100 μM

10 μM

Table 6.1: Concentration at which the drug alone did not decrease cell viability.
MTT-assay was performed to examine the effect of increasing concentrations of
doxorubicin, paclitaxel, and carboplatin in MDA-MB-231 and BT-549 cells. The maximum
concentration to produce no significant reduction in cell viability was selected and these
concentrations are summarized in the table.
6.3.2 Cotreatment with low doses of kinase inhibitors and doxorubicin produces
toxicity in both MDA-MB-231 and BT-549 cells.
MDA-MB-231 and BT-549 cells were treated with increasing concentrations (0.01,
0.03, 0.1, 0.3, and 1 μM) of the ERK5 inhibitor XMD8-92, the MEK1/2 inhibitor trametinib,
and the AKT inhibitor ipatasertib. These doses of inhibitors did not decrease TNBC cell
viability (Figure 6.3). DMSO or low-dose doxorubicin were added to TNBCs treated with
the various doses of kinase inhibitors (Table 6.1). After 72 hours of treatment, MTT assay
was performed to assess cell viability. Cotreatment with low dose of doxorubicin
sensitized MDA-MB-231 and BT-549 cells to low doses of XMD8-92 (Figure 6.3 A, D).
Trametinib and ipatasertib alone decreased MDA-MB-231 cell viability even at low doses.
Doxorubicin did not enhance the toxicity of either kinase inhibitor (Figure 6.3C). In BT549 cells, trametinib and ipatasertib did not produce decreases in cell viability on their
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own. However, in combination with low dose doxorubicin both trametinib and ipatasertib
significantly decreased in cell viability in BT-549 cells (Figure 6.3F).

Figure 6.3: Effect of doxorubicin in combination with kinase inhibitors at 72 hours.
Data represent the ± SEM of three independent experiments as a percentage of untreated
DMSO control group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 combination vs. drug
alone determined by two-way ANOVA with the Bonferroni post hoc test.
6.3.3 Single pathway kinase inhibitors do not enhance paclitaxel or carboplatin
sensitivity in TNBC cells:
Similar as described above, TNBC cells were treated with paclitaxel or carboplatin
in combination with kinase inhibitors. With the exception of potentiation at low doses of
XMD8-92 in MD-MB-231 cells, cotreatment with paclitaxel or carboplatin and the kinase
inhibitors did not significantly decrease cell viability (Figure 6.4 and 6.5). Interestingly,
there was an antagonistic interaction between trametinib and paclitaxel or carboplatin
because combination with paclitaxel or carboplatin reduced the ability of trametinib to
decrease cell viability in MDA-MB-231 cells.
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Figure 6.4: Effect of paclitaxel in combination with kinase inhibitors at 72 hours.
Data represent the ± SEM of three independent experiments as a percentage of untreated
DMSO control group. *p<0.05; **p<0.01 combination vs. drug alone determined by twoway ANOVA with the Bonferroni post hoc test.

Figure 6.5: Effect of carboplatin in combination with kinase inhibitors at 72 hours.
Data represent the ± SEM of three independent experiments as a percentage of untreated
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DMSO control group. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 combination vs. drug
alone determined by two-way ANOVA with the Bonferroni post hoc test.

The drug efflux transporters, MDR1 and MRP1, are major drivers of
chemotherapeutic resistance in several cancers. Inhibition of ERK5 signaling was shown
to inhibit the activity of MDR1, which, in turn, increased the influx of doxorubicin into breast
and lung cancer cells.143 Therefore, we hypothesized that MAPK inhibitors will decrease
MDR1 and MRP1 expression to increase the efficacy of low dose chemotherapeutics.
Surprisingly, XMD8-92 and trametinib increased MDR1 and MRP1 expression in MDAMB-231cells (Figure 6.6). In contrast, trametinib decreased MRP1 expression in BT-549
cells (Figure 6.6D). Ipatasertib did not alter MDR1 or MRP1 expression in either TNBC
cell line.
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Figure 6.6 XMD8-92 and trametinib modulate the expression of drug efflux
transporters in TNBC cells. Trametinib and XMD8-92 increase (A) MDR1 and (B) MRP1
expression in MDA-MB-231 cells, while trametinib decreases MRP1 expression in (C-D)
BT-549 cells.
6.4 Discussion
In this study we evaluated whether low-dose chemotherapeutic drugs could
enhance the efficacy of kinase inhibitors on cell viability in TNBC. MDA-MB-231 cells were
less sensitive to toxic effects of doxorubicin and carboplatin compared to BT-549 cells.
One of the reasons accounting for the difference could be the anatomical origin of the two
models. MDA-MB-231 cells are derived from metastatic pleural effusions whereas BT549 cells are derived from primary breast tumor. Since MDA-MB-231 cells are derived
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from a metastatic site, these cells may be more aggressive and resistant to the toxic
effects of chemotherapy.
Trametinib was found to have an antagonistic interaction with paclitaxel and
carboplatin in MDA-MB-231 cells. Doxorubicin, paclitaxel, and carboplatin are known
chemotherapeutic substrates for MDR1 and/or MRP1, respectively. 144 One of the possible
mechanisms is upregulation of the drug efflux transporters MDR1 and MRP1 by
trametinib. Since trametinib decreased MRP1 expression in BT-549 cells, this may be
one possible mechanism for increase in sensitivity to cotreatment with doxorubicin or
carboplatin and trametinib in BT-549 cells.
Ipatasertib combined with the chemotherapeutic drugs was not effective at
decreasing cell viability in TNBC cells. Ipatasertib did not alter the expression of the efflux
transporters in either cell line. One of the reasons why cotreatment with ipatasertib with
doxorubicin, paclitaxel, or cisplatin did not induce cell death may be that there are
compensatory increases in alternative pathways, including the MEK5-ERK5 pathway
following AKT inhibition by ipatasertib. In fact, dual ERK5 and AKT inhibition has been
shown to increase paclitaxel sensitivity in TNBC.145 In the next chapter, we examine the
effect of dual MEK5/PI3K inhibitors on the sensitivity of chemotherapeutic drugs in TNBC.
In conclusion, our combination data suggest that kinase inhibitors could be
combined with chemotherapeutic drugs at low doses. Most chemotherapeutic drugs and
kinase inhibitors are administered to the patients at the maximum tolerated dose. We
have shown that same effect at higher doses of single drug could be recapitulated at
lower doses of chemotherapeutic drug and kinase inhibitor. This approach could be
beneficial to prevent collateral toxicity in healthy tissues.
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Chapter 7: Evaluation of novel dual MEK5/PI3K quinazoline inhibitors in TNBC
7.1 Introduction
Triple negative breast cancer (TNBC) is in dire need for alternative therapies.
Patients with TNBC expressing increased MEK5 display reduced relapse-free survival
and increased mortality.146 MEK5 is a serine/threonine protein kinase in the three-tiered
mitogen activated protein kinase (MAPK) cascade that proceeds from external growth
receptor signaling to ultimately mediate cell growth, invasion, and metastasis. Although
inhibiting MEK5/ERK5 would seem to be an ideal strategy for TNBC therapies,
suppression of the MEK5/ERK5 pathway causes a compensatory increase in the activity
of the well-known oncogene AKT. Dual inhibition of ERK5 and AKT pathways using
known pharmacological inhibitors has been shown to decrease cell viability and decrease
off-target toxicity.147 Therefore, we developed novel small molecule dual ERK5/AKT
inhibitors in collaboration with the Flaherty lab to target TNBCs.
Our approach was to canvas the literature for known MEK5 inhibitors. The Binding
Database identified a compound (Figure 7.1) from the Craig Thomas lab with off-target
MEK5 inhibition (MEK5 IC50=20 µM).

The Thomas lab forwarded a sample of the

compound while we conducted a re-synthesis. MEK5 inhibition in our cellular inhibition of
was identical for each compound preparation. Subsequent analog synthesis from the
lead compound and testing has generated over 70 compounds. These compounds were
initially tested for MEK1,2 and 5 inhibition at a single dose of 10 µM as well as for
alterations of pAKT, an indicator of AKT pathway activation.
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Figure 7.1: Compound from Rosenthal and colleagues.
Selected compounds from the quinazoline series identified compounds were
inhibitors of the AKT pathway at the level of PI3K. Additionally, two of the selected
compounds, SP-1-90 and SP-1-177 displayed both PI3K isoform selectivity and MEK5
inhibition. The cellular IC50 values were determined for SP-1-90 and SP-1-177.
Moreover, the lead compounds were evaluated for their effects on cell viability and
chemotherapeutic sensitivity in MDA-MB-231 and BT-549 cells.
7.2 Hypothesis
Chemotherapeutic drugs will enhance the effect of dual MEK5/PI3K inhibitors on cell
viability in triple-negative breast cancer cells.
7.3 Results
7.3.1 Identification of quinazolines as dual ERK5/AKT inhibitors
MDA-MB-231 cells (500,000 cells/well) were cultured in a 6-well plate for 24 hours.
To examine kinase activity or inhibition, the cells were serum-starved for 18-24 hours.
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The quinazoline inhibitors (10 µM concentration) were added for 30 minutes prior to EGF
(100ng/ml) stimulation for 15 minutes. Cell lysates were collected and examined for
phospho- and total ERK5, ERK1/2, and AKT kinases using standard western blot
procedure. Selected compounds were tested for EGFR activation to rule out off-target
effects since the quinazoline core is conserved in several EGFR inhibitors. Substitution
of hydrogen in K37 with a methyl group diminished EGFR activity while gaining ERK5
selectivity (Figure 7.2). The structures and results are summarized in appendix C.

Figure 7.2. Structures and kinase activity data for quinazoline series. K36 was resynthesis of the Rosenthal compound and used as a positive control to inhibit ERK5.
7.3.2 Potency of lead compounds
Inhibitors SP-1-190 (K33) and SP-1-182 (K46) were selected based on their kinase
inhibition profiles (selective ERK5 and AKT inhibition). These compounds were further
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evaluated to determine their IC50 values for ERK5, AKT, and cell viability inhibition (Figure
7.3).

Figure 7.3 SP-1-177 and SP-1-182 are potent dual MEK5/PI3K inhibitors.
7.3.3 Doxorubicin enhances sensitivity of SP-1-177 in MDA-MB-231 cells
The lead compounds from diphenylamine (SC-1-181), thiophene (MG-5-5), and
quinazoline

(SP-1-77

and

SP-1-182)

series

were

combined

with

low-dose

chemotherapeutic drugs paclitaxel, doxorubicin, and carboplatin to examine synergy in
MDA-MB-231 and BT-549 cells. We found that SP-1-177, a dual MEK5/AKT inhibitor
enhanced doxorubicin sensitivity in MDA-MB-231 cells (Figure 7.2.2). While SP-1-171
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alone significantly decreased cell viability in BT-549 cells, there was no further reduction
in cell viability observed in combination with chemotherapeutic drugs. SC-1-181 and SP1-90 enhanced doxorubicin sensitivity in BT-549 cells.

Cell viability (% DMSO)

MDA-MB-231

[Ptx], 100 pM
[Dox], 100nM

150

100

[Carbo], 100 µM
**

*** **

***

*

*

**

50

**

## ***
**

0
[SC-1-181], 1µM

[MG-5-5], 1µM

[SP-1-90], 1µM

[SP-1-177], 1µM

Figure 7.4: Effect of novel MAPK inhibitors in combination with chemotherapeutic
agents on cell viability. (A) MDA-MB-231 and (B) BT-549 cells were treated with 1μM
novel inhibitor in the presence of DMSO or low-dose paclitaxel, doxorubicin, and
carboplatin for 72 hours. MTT assay was performed to assess cell viability. Data
represent the +/- SEM of three different experiments determined by one-way ANOVA with
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the Bonferroni post hoc test. *p<0.05; **P<0.01; ***P<0.001; ****P<0.0001 vs DMSO;
#P<0.05, ##P<0.01; ####P<0.0001; vs individual drug determined by one-way ANOVA
with the Bonferroni post hoc test.
7.4 Discussion
Due to crosstalk between the ERK5 and AKT pathways, it is important to develop
dual targeting agents to simultaneously target both the pathways. In the current chapter,
through structure-activity relationships studies, novel MEK5/PI3K inhibitors were
identified and characterized for their selective activity against ERK5 and AKT, the
downstream substrates of MEK5 and PI3K, respectively. In the previous chapter, we
observed

synergy

with

single

agent

kinase

inhibitors

in

combination

with

chemotherapeutic drugs. Addition of a pan-PI3K inhibitor GD-0941 to docetaxel showed
synergy in mouse xenograft models.148 Clinically, BMK120, a pan-PI3K inhibitor and
paclitaxel combination reversed paclitaxel drug resistance in patients with advanced solid
tumors.149 Paclitaxel was found to enhance cytotoxicity by ipatasertib and XMD8-92
combination in MDA-MB-231 cells.145 The effect of chemotherapeutic drugs on cytotoxic
effects of dual MEK5 and PI3K inhibitors in TNBC is currently unknown. In this study, we
combined the chemotherapeutic drugs with lead MEK5 inhibitors or dual PI3K inhibitors
from the diphenylamine,83 thiophene,150 and quinazolines at low doses and examined
their effect of on cell viability.
While doxorubicin did not sensitize the effect of MEK5 inhibitor SC-1-181 on cell
viability, doxorubicin significantly enhanced the sensitivity of MDA-MB-231 cells to a dual
MEK5/PI3K inhibitor SP-1-177. SP-1-177 produced a greater reduction in cell viability
compared to SP-1-90 in BT-549 cells. There was no further reduction after addition of
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chemotherapeutic drugs in BT-549 cells. In this study, the chemotherapeutic drugs and
kinase inhibitors were added simultaneously. Sequence of drug administration could alter
cellular response.151 Future studies focus on examining the effect of sequential addition
of drugs on cell viability.
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Chapter 8: Dual inhibition of MEK5 and MEK1/2 or PI3K pathways decreases cell
viability, proliferation, migration, and stemness, and induces mesenchymal to
epithelial transition in glioblastoma multiforme
8.1 Introduction
Glioblastoma multiforme (GBM) is a very aggressive form of cancer with median
survival of only 14-15 months despite standard therapy consisting of surgery, adjuvant
radiation, and chemotherapy. Infiltration into surrounding tissue decreases the success
of surgical removal of the tumor and further increases the rate of recurrence. 152-153
Hyperactivation of PI3K and MAPK pathways is a frequent event in most GBM cases.
Moreover, the mesenchymal subtype of GBM is driven by activation of the ERK1/2
pathway.154 Figure 8.1 summarizes the tumorigenic effects regulated by ERK1/2 pathway
in glioblastoma.
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Figure 8.1: ERK pathway in GBM.154
The goals of the current research are to identify therapeutic targets and
interventions for the treatment of glioblastoma multiforme, which has the worst prognosis
and decreased overall survival compared to other brain cancers. There are no current
therapies that are effective to treat patients with GBM. There is an urgent need to identify
relevant targets that can be inhibited therapeutically to improve prognosis of GBM
patients. MAPK and PI3K pathways are recently identified to promote GBM
progression.155 We first utilized a bioinformatics approach to compare genes downstream
of MAPK and PI3K pathways and those involved EMT and proliferation in healthy versus
GBM tumor samples using publicly available datasets. The MAPK7 gene codes for the
newest member of the MAPK pathway, extracellular signal-regulated kinase ERK5, and
is significantly upregulated in GBM tumor samples compared to healthy control. GBM
tumor samples were enriched in EMT markers and genes involved in cell proliferation,
which are known downstream targets of MAPK and PI3K pathways.
Activation of AKT is an important event in GBM progression due to mutation in
PTEN or PI3K. One of the limitations of PI3K pathway inhibitors is compensatory
increases in alternative pathways, including the MEK5-ERK5 pathway.145 This
necessitates the development of novel and relevant combination strategies to target
GBM. We have previously shown that dual inhibition of AKT and ERK5 or triple inhibition
of AKT, ERK5, and BRD4 is a relevant strategy to target triple-negative breast cancer
(TNBC).145 Moreover, the crosstalk between ERK5 and AKT pathways has been
previously noted in neuroblastomas.39 Therefore, we evaluated the effect of dual inhibition
of ERK5 and AKT pathways on cell viability, proliferation, and migration in GBM. MYC is
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a major oncogenic driver in GBM, which was found to be upregulated and positively
correlated with MAPK7 in GBM patient samples. Bromodomain inhibitors were developed
with a rationale to target the MYC oncogene in cancer.156 Therefore, a dual MEK5/PI3K
inhibitor J19 (MG-3-81)150 was used alone and in combination with CPI-203, a BRD4
inhibitor. We also examined the effects of previously reported novel inhibitors of MEK5 or
MEK1/2 pathways, which reversed the mesenchymal phenotype of TNBC157 on EMT in
GBM.
8.2 Hypothesis
Dual inhibition of the MEK5 and MEK1/2 or PI3K pathways will induce MET and decrease
cell viability, proliferation, migration, and colony formation in PTEN mutant GBM cells with
a mesenchymal phenotype.
8.3 Results
8.3.1 MAPK7 gene expression is significantly upregulated in GBM tumor samples
compared to healthy groups
Glioblastoma multiforme (GBM) was identified to have the worst prognosis among
other forms of cancers that originate in the brain (Figure 8.2A). MAPK7 gene, which codes
for protein ERK5 was found to be significantly upregulated in GBM tumor samples
compared to healthy group (Figure 8.2B). In contrast, MAPK1 and MAPK3 genes were
significantly downregulated in GBM vs. healthy group. Epithelial cell markers CDH1 and
keratin 1 (KRT1) were significantly downregulated, whereas tight junction protein (TJP1)
gene expression did not decrease in GBM versus healthy group. Mesenchymal cell
marker vimentin (VIM) and stem cell marker PROM1 were significantly upregulated. As
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expected, genes involved in cell proliferation KI67, CCND1, and PCNA were significantly
upregulated in GBM versus healthy group. Upstream regulator of MAPK pathway, EGFR
was significantly upregulated while there was no increase in PIK3CA gene; however,
there was a significant decrease in PTEN gene, which inhibits AKT activation by
dephosphorylation. There was a significant increase in AKT1 and AKT2 and decrease in
AKT3 gene expression (Figure 8.2B).
8.3.2 MAPK7 gene expression positively correlates with the EMT markers in GBM
tumors
ERK5 is known to antagonize the decrease in MYC induced by KRAS suppression,
indicating that ERK5 may be upstream of MYC.53 Interestingly, there was a significant
positive correlation between MAPK7 and MYC in GBM. To understand whether ERK5
regulates genes involved in EMT and stemness, MAPK7 gene expression was correlated
to stem cell markers PROM1 (gene that codes for CD133), NOTCH1, epithelial cell
marker CDH1 (gene that codes for E-cadherin), and mesenchymal markers VIM and
ZEB1. MAPK7 gene expression negatively correlated with CDH1 (Figure 8.2D) and
positively correlated with stemness markers PROM1 and NOTCH1 (Figure 8.2E, H) and
mesenchymal markers VIM and ZEB1 (Figure 8.2F, G), suggesting a role for ERK5 in
mediating EMT and stemness in GBM.
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Figure 8.2. Comparison of genes downstream of MAPK and PI3K pathways in
tumors derived from GBM patients versus healthy groups. (A) Kaplan-Meier survival
analysis in different subtypes of brain cancer (B) Gene expression analyses in healthy
tissues versus GBM patient samples. Gene correlation between MAPK7 and (C) PROM1
(D) CDH1, (E) MYC (F) VIM, (G) ZEB1, or (H) NOTCH1. Data were plotted using R2:
Genomics
analysis
and visualization platform (https://hgserver1.amc.nl/cgibin/r2/main.cgi). Datasets were exported from Tumor Brain (REMBRANDT study) Madhavan - 550 - MAS5.0 - u133p2.

8.3.3 MAPK1, MAPK7, AKT1, and AKT2 gene expression is associated with poor
patient survival in GBM
Kaplan Meier survival analysis was performed to examine the association of MAPK
and PI3K pathways on overall survival in GBM using publicly available datasets. High
MAPK1 (gene that codes for ERK2), MAPK7 (gene that codes for ERK5), AKT1 and AKT2
expression was associated with worse patient outcome whereas high MAPK3 (gene that
codes for ERK1) and AKT3 expression was associated with better patient outcome
(Figure 8.3). Overall, these data suggest that ERK5 and AKT1 and 2 are important targets
in GBM.
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Figure 8.3. MAPK3, MAPK1, and MAPK7 expression correlates with poor patient
survival in GBM. Disease free survival was analyzed using R2: Genomics analysis and
visualization platform (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Datasets were
exported from Tumor Brain (REMBRANDT study) - Madhavan - 550 - MAS5.0 - u133p2.

8.3.4 Dual inhibition of ERK5 and AKT pathways synergistically reduces cell
viability in GBM
U87MG cells are PTEN mutant and may rely on the AKT pathway for survival and
proliferation. Since crosstalk between AKT and ERK5 may exist, the effects of ipatasertib,
an AKT inhibitor and XMD8-92, an ERK5 inhibitor alone and in combination were
examined on kinase activation, cell viability, and migration. To determine the specificity
of kinase inhibitors, U87MG cells were serum starved for 18 hours after 24 hours of cell
seeding and treated with kinase inhibitors for 30 minutes. Cells were stimulated with EGF
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for 15 minutes. Cell lysates were collected and examined for ERK1/2, ERK5, and AKT
activation. As expected, XMD8-92 and XMD8-92+ipatasertib groups decreased ERK5
activation with no effect on AKT or ERK1/2 activation. Ipatasertib targets the ATP-site
and keeps AKT in its active form and decreases downstream signaling by AKT. This may
explain while there was no decrease in AKT activation, there was still a decrease in cell
viability after treatment with ipatasertib. Ipatasertib modestly increased ERK5 activation
(Figure 8.4A). Neither of the inhibitors altered ERK1/2 activity. Targeting AKT alone led
to compensatory increase in ERK5 activation, which was inhibited in the Ipat+XMD8-92
group compared to control (Figure 8.4A).
While both ipatasertib and XMD8-92 were effective at decreasing cell viability in a
concentration-dependent manner (Figure 8.4B-C), combination of ipatasertib with XMD892 produced a greater reduction in cell viability. 1:3 combination of ipatasertib and XMD892 was more effective than 1:1 ratio at increasing the fraction affected as calculated by
using CompuSyn software (Figure 8.4D). While ipat or XMD8-92 did not decrease cell
migration alone, the combination significantly decreased cell migration in U87MG cells.
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Figure 8.4. Dual ERK5 and AKT decreases cell viability and migration in U87MG
GBM cells. (A) Western blot analysis of ERK5, ERK1/2, and AKT activation by EGF in
U87MG cells (B) Cells were treated with XMD8-92 and ipatasertib at increasing
concentrations for 72 hours. Data represent the ± SEM of three different experiments for
each inhibitor compared to DMSO control. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001
vs DMSO control group determined by one-way ANOVA with the Bonferroni post hoc test.
(C) Combination index table for synergy determination. (D) Effect of ipatasertib and
XMD8-92 at 1 and 3 μM concentration, respectively on cell migration in U87MG cells.
Scratches were made after 24 hours of cell seeding (0h) and cells were treated with the
kinase inhibitors for 24 hours. Cells were imaged at the time of scratch (0 h) and after 24
hours from the time of scratch (20X magnification). (Synergy data: Dr. Thomas Wright)

Ipat+XMD combination did not significantly decrease the proliferative fraction (Figure 8.5),
indicating that alternative pathways may regulate cell proliferation in GBM.
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Figure 8.5: Ipat+XMD combination does not decrease proliferative fraction in
U87MG cells. (Katie Anna). Cells were treated with indicated inhibitors for 72 hours (20X
magnification). Proliferative fraction was evaluated as the number of Ki67 positive cells
divided by the number of Hoechst positive cells. Data represent the ± SEM of three
different experiments. *p<0.05; **p<0.01; ***p<0.001 vs. DMSO control group determined
by one-way ANOVA with the Bonferroni post hoc test.
8.3.5 Dual PI3K/MEK5 inhibitor+CPI203 combination significantly decrease cell
proliferation via p21 restoration in GBM
BRD4 regulates cell cycle progression via upregulation of c-Myc and cyclinD1,
which are also downstream targets of MAPK pathways. Several dual PI3K/MEK5
thiophene analogs were developed as novel therapeutic interventions to target cancer. In
this study, we examined the effect of novel dual MEK5/PI3K inhibitor J19 (MG-3-81) in
combination with BRD4 inhibitor CPI-203 on cell proliferation. Ipatasertib, J19 (MG-3-81),
or CPI-203 alone did not significantly decrease the proliferative fraction as determined by
taking the ratio of Ki67+ cells to Hoechst+ cells. While ipatasertib did not potentiate the
effect of CPI203 on cell proliferation, J19 (MG-3-81)+CPI-203 combination significantly
decreased proliferative fraction to a greater extent compared to either drug alone (Figure
8.6A). The decrease in cell proliferation correlated with an increase in p21, a cell cycle
inhibitor (Figure 8.6B).
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Figure 8.6. Effect of ipatasertib and J19 (MG-3-81) alone and in combination with
CPI-203 on cell proliferation and p21 expression in U87MG cells. (A) Cells were
treated with indicated inhibitors for 72 hours (20X magnification). Proliferative fraction was
evaluated as the number of Ki67 positive cells divided by the number of Hoechst positive
cells. Data represent the ± SEM of three different experiments. *p<0.05; **p<0.01;
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***p<0.001 vs. DMSO control group determined by one-way ANOVA with the Bonferroni
post hoc test. (Seraina Schottland).

8.3.6 Dual MEK1/2 and MEK5 inhibitor(s) and LBH589 (HDAC inhibitor) induce MET
in U87MG glioblastoma cells.
Reversing EMT is an emerging approach to target cancer. We have previously
shown that pharmacological inhibitors of MEK1/2 and MEK5 pathways reversed EMT in
triple-negative breast cancer.157 U87MG cells were treated with novel MEK1/2 inhibitor
(SC-1-122), MEK5 inhibitor (SC-1-181), dual MEK1/2 and MEK5 inhibitor (SC-1-151),
LBH589, trametinib, or XMD8-92 for 72 hours. The phenotypic switch from mesenchymal
to epithelial was most prominent in SC-1-151, trametinib, and LBH-589-treated groups
(Figure 8.7A-B). We hypothesized that targeting the AKT pathway may be a relevant
strategy to reverse EMT; however, ipatasertib, J19 (MG3-81), or CPI-203 did not reverse
EMT in these cells (Figure 8.7A). Therefore, the ERK1/2 and ERK5 pathways may play
a larger role in the EMT than the AKT pathway.
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Figure 8.7: Effect of novel and known MAPK inhibitors on MET in U87MG cells. (A)
U87MG cells were treated with MAPK inhibitors for 72 hours and stained with crystal violet
after 72 hours of treatment. (B) Cell morphology was quantified by morphometric analysis
10X (Jordan Martin).
8.3.7 Trametinib decreases ERK5 activation, cell viability, migration, and colony
formation in GBM
Since trametinib was most effective at reversing EMT, we further characterized its
effects on kinase activation by EGF to determine its specificity, and cell viability,
migration, and colony formation assays. U87MG cells were serum starved for 18 hrs and
treated with trametinib at 0.1 and 1 μM concentrations for 30 minutes. Cells were then
stimulated with EGF for 15 minutes. Lysates were collected and examined for ERK5,
ERK1/2, and AKT activation. As expected, trametinib decreased ERK1/2 activation by
EGF. Surprisingly, trametinib also inhibited ERK5 activation by EGF (Figure 8.8A). MTT,
migration, and colony formation assays were performed to examine the effects of
trametinib on U87 cells in 2D and 3D cultures. Trametinib modestly decreased cell
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viability at 10 μM concentration (Figure 8.8B) and significantly inhibited cell migration and
colony formation, consistent with its effect on MET in U87MG cells (Figure 8.8C-D).

Figure 8.8. Trametinib decreases ERK5 activation, cell viability, migration, and
colony formation in U87MG cells. (A) ERK5 and ERK1/2 activation (B) cell viability (C)
migration (D) colony formation and CD133 expression in U87MG GBM cells. **p<0.01 vs
control group determined by Student’s t-test.
8.4 Discussion
Glioblastoma multiforme is an aggressive disease with limited therapeutic options.
ERK1/2, ERK5, and AKT pathways are important targets in glioblastoma. However, the
crosstalk between ERK5 and AKT and effects of MAPK inhibitors on proliferation, EMT,
and stemness in glioblastoma are not well-understood. Therefore, we examined the effect
of novel and known MAPK pathway inhibitors in combination with PI3K pathway
inhibitor(s) on viability, migration, EMT, and stemness in U87 GBM cells.
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Recent studies suggest that ERK5 expression and activation are crucial events in
regulating EMT in several cancers90, 105 and targeting the MAPK pathways has been
shown to reverse EMT in breast cancer.157-158 One goal of this research was to identify
pathways that were significantly upregulated in GBM compared to healthy controls, so as
to therapeutically target the aberrant pathways. Recent evidence suggests that EGFR,
PI3K, and PTEN mutations159 are common oncogenic drivers in GBM, making GBM a
relevant disease model to study ERK1/2, ERK5, and AKT protein kinases as relevant
drug targets in GBM. From our research, using publicly available datasets from Gusev et
al.,160 we examined specific components of MAPK and PI3K pathways, which were
upregulated in GBM versus healthy control.
MAPK7 was found to be significantly upregulated in GBM versus healthy control.
Therefore, we correlated MAPK7 gene expression to EMT and proliferation markers.
There was a significant increase in the upstream regulator of MAPK pathways, epidermal
growth factor receptor (EGFR), in agreement with previous reports. 161
PTEN deletion is a common event in GBM.159 Since PTEN expression was
significantly downregulated in GBM versus healthy control, AKT may be a relevant target
in GBM. Moreover, high AKT1 and AKT2 expression was associated with worse patient
outcome. Since high MAPK3 and AKT3 gene expression correlated with better patient
outcome, it may be important to develop isoform-specific pharmacological inhibitors of
ERK1, AKT1, or AKT2, which spare ERK2 or AKT3 activity. Isoform-specificity of
inhibitors are currently being investigated in our laboratory and others.162 Data suggest it
may be important to determine which tumor subtypes may benefit most from isoformspecific compounds.
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While we obtained information about putative drug targets by utilizing a
bioinformatics approach, these observations do not provide insights into whether there is
a subsequent increase in protein expression or activation in different components of the
MAPK and PI3K pathways. Therefore, we utilized an in vitro approach to inhibit these
pathways using known and novel inhibitors of the MAPK and PI3K pathways to examine
their effect on kinase activation, proliferation, EMT, and stemness.

To understand

whether targeting ERK5, ERK1/2, and/or PI3K pathways was promising in GBM, we
utilized PTEN-mutant U87MG cells with moderate EGFR expression and a mesenchymal
phenotype.163-164 In addition to genes involved in the regulation of proteins that promote
EMT, cell proliferation genes downstream of MAPK, AKT, and bromodomain pathways
were significantly enriched in GBM tumors compared to healthy control. Compensatory
activation of the AKT or BET proteins may reactivate MAPK-mediated proliferation in
cancer cells.129 Therefore, combination strategies were designed to target both MAPK
and bromodomain proteins in U87MG cells. Similar to our findings in breast cancer, dual
ERK5 and AKT inhibition significantly decreased cell viability and migration in U87MG
cells. Novel dual PI3K/MEK5 inhibitor J19 (MG-3-81) was more effective in combination
with BRD4 inhibitor CPI-203 to decrease cell proliferation compared to AKT inhibitor
ipatasertib. Our data suggest that this decrease in cell proliferation was mediated at least
in part via p21 restoration.
U87MG cells were especially susceptible to dual targeting of ERK1/2 and ERK5
pathways since treatment with dual MEK1/2 and MEK5 inhibitor significantly decreased
the percentage of cells with SI>3 when compared with DMSO control or inhibition
ofMEK1/2 or MEK5 alone (SC-1-122 or SC-1-181, respectively). Although MAPK7 gene
155

expression significantly correlated with mesenchymal markers ZEB1, vimentin, and
inversely correlated with epithelial marker E-cadherin, MEK5 inhibitor SC-1-181 did not
reverse EMT in U87MG cells. This may be because ERK1/2 pathway is still active.
Trametinib, a MEK1/2 inhibitor reversed EMT in U87MG cells. To our knowledge, this is
the first study to show the effect of MEK1/2 inhibition on reversal of EMT in glioblastoma.
A previous study has reported that downregulation of ERK5 by microRNA-200
suppressed EMT in GBM.44 This may indicate that total ERK5 expression, rather than its
activation may be a driver of EMT in GBM. Trametinib decreased total ERK5 expression
even at short time points (Figure 8.8A), which may indicate that inhibition and decrease
in total ERK5 expression may be necessary for full effect of trametinib on MET in U87MG
cells. LBH589, a histone deacetylase inhibitor was used as a positive control since it
known to reverse EMT in some cancers.165 The possible reasons why ERK5 inhibition
alone did not reverse EMT may be because total ERK5 expression may regulate
transcription of genes in the nucleus even in the absence of phosphorylated ERK5 in the
cytosol.166
MEK1/2 inhibitor trametinib decreased ERK1/2 and ERK5 activation in response
to EGF. ERK1/2 and ERK5 pathways share ~50% sequence homology at the N-terminal
domain.167 Trametinib-mediated decrease in ERK5 activation may be mediated via
MEK1/2 inhibition. Trametinib decreased viability, migration, and colony formation in
U87MG cells, indicating that dual MEK1/2 and MEK5 inhibition is a relevant strategy to
target EMT in GBM. Overall, our data suggest that ERK1/2 and ERK5 are relevant targets
to reverse the EMT and ERK5 and AKT are relevant targets to decrease cell viability and
proliferation in glioblastoma cells with a mesenchymal phenotype (Figure 8.9). In
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conclusion, this is the first study to examine the effects of pharmacological inhibition of
MEK5 and MEK1/2 or PI3K pathways on cell proliferation, migration, stemness, and EMT
in GBM.

Figure 8.9: Regulation of cell viability, EMT, and stemness via the MAPK and PI3K
pathways in GBM.
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Chapter 9: Marine cyanobacteria inhibit cell viability and enhance
chemotherapeutic sensitivity in triple-negative breast cancer
9.1 Introduction
TNBCs are in dire need for alternative therapies. There is also an urgent need to
identify novel targets to develop treatment options, which can selectively target cancer
cells. A recent review of the literature168 has identified a number of marine cyanobacterial
peptide and peptide-containing natural compounds that display antitumor cytotoxicity.
Sigma-2 receptors was identified as transmembrane protein 97.169 In this chapter, we will
discuss the effects of novel marine peptides, veraguamide M and N, that are putative
ligands for sigma-2 receptors, which are overexpressed in TNBCs and promote
tumorigenesis. Moreover, sigma 2 receptor ligands have been shown to be toxic in
neuroblastoma, and mouse breast cancer cell lines. 170-171 Sigma 2 receptor selective
compounds have also been reported to decrease MCF-7 and doxorubicin-resistance
MCF7 breast cancer cell proliferation and enhance the sensitivity of MCF-7 cells to
doxorubicin21,22. Currently, there is only one study that examines the synergistic effects
of sigma 2 receptor ligands with PARP inhibitors in MDA-MB-231 TNBC cells and one
other study that examines synergy with taxol and a cytotoxic payload delivered to TNBC
cells via conjugation to a sigma 2 receptor ligand23. In this study, we examined the
expression of TMEM97, a gene that codes for sigma 2 receptors, in breast cancer
subtypes. Next, we examined the effect of novel sigma 2 ligands on cell viability and
chemotherapeutic sensitivity in triple-negative breast cancer cells.
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9.2 Hypothesis
Chemotherapeutic drugs will enhance cytotoxic effects of novel sigma 2 receptor ligands
in triple-negative breast cancer cells.
9.3 Results
9.3.1 High expression of TMEM97 in diverse breast cancer subtypes is associated
with poor overall survival
Bioinformatic analyses of publicly available datasets from Bertucci and
colleagues 109 was performed to determine the expression of TMEM97 in diverse breast
cancer subtypes. TMEM97 expression was higher in luminal a, luminal b, erbb2, and
basal like cancers compared to normal (Figure 9.1A). Higher expression of TMEM97 also
decreased disease free survival as compared to breast cancer patients with low tumore
expression of TMEM97.
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Figure 9.1: TMEM97 is overexpressed in cancer versus healthy groups and high
TMEM97 expression correlates with poor overall survival in breast cancer patients.
(A) TMEM97 is overexpressed in cancer versus healthy control (B) High TMEM97
expression correlates with poor patient survival in breast cancer. Disease free survival
was analyzed using R2: Genomics analysis and visualization platform
(https://hgserver1.amc.nl/cgi-bin/r2/main.cgi). Datasets were exported from Tumor
Breast (MDC) Bertucci - 266 - MAS5.0 - u133p2.
9.3.2 Marine cyanobacteria inhibit viability in MDA-MB-231 cells
MDA-MB-231 cells were treated with marine cyanobacteria fractions at 0.1, 1, and
10 ug/ml concentrations for 72 hours. MTT assay was performed to determine cell
viability. Fractions B, C, D, E, and F significantly decreased cell viability (Figure 9.2).
Barbamide was extracted from fraction F to determine its effect on cell viability.
Barbamide produced a significant decrease in cell viability in MDA-MB-231 and BT-549
cells (Figure 9.2).
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Figure 9.2: Barbamide produced a concentration-dependent decrease in cell viability in

MDA-MB-231 cells after 72 hours of treatment. Data represent the ± SEM of three different
experiments. *p<0.05; **p<0.01; ****p<0.0001 vs control group determined by one-way ANOVA
with the Bonferroni post hoc test.

9.3.3 Effect of marine cyanobacteria in combination with chemotherapy on TNBC
cell viability
Sigma 2 receptor ligands have been shown to synergize with doxorubicin to inhibit cell
growth in MCF-7 cells.172 However, studies of synergy of sigma 2 ligands with
doxorubicin, paclitaxel, and cisplatin in TNBC have not been done. Therefore, we
combined two natural sigma 2 receptor ligands veraguamide and barbamide with
chemotherapeutics, doxorubicin, paclitaxel, and carboplatin at low doses. The toxic effect
of veraguamide was enhanced by doxorubicin and carboplatin in MDA-MB-231 and BT549 cells. The toxic effects of barbamide was enhanced by doxorubicin and carboplatin
in BT-549 cells (Figure 9.3 and Figure 9.4).
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Figure 9.3: Effect of (A) veraguamide and (B) barbamide on chemotherapeutic
sensitivity in MDA-MB-231 cells. Data represent the ± SEM of three different
experiments. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 vs control group #p<0.05;
###p<0.001; ####p<0.0001 vs chemotherapeutic drug alone determined by one-way
ANOVA with the Bonferroni post hoc test.
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Figure 9.4: Effect of (A) veraguamide and (B) barbamide on chemotherapeutic
sensitivity in BT-549 cells. Data represent the ± SEM of three different experiments.
*p<0.05; **p<0.01; ***p<0.001 vs control group #p<0.05; ##p<0.01; ###p<0.001;
####p<0.0001 vs chemotherapeutic drug alone determined by one-way ANOVA with the
Bonferroni post hoc test.
9.4 Discussion
Novel cyanobacterial compounds have been identified as sigma 2 receptor ligands.
From the initial screen of cyanobacterial fractions, barbamide was isolated from fraction
F. Veraguamide and barbamide were used at low doses in combination with
chemotherapeutic drugs. There was a modest increase in cytotoxicity of veraguamide
and barbamide by carboplatin and doxorubicin. In future, more potent analogs of
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barbamide will be synthesized as putative sigma 2 receptor ligands as alternative
therapies for diverse breast cancer subtypes. Since natural compounds may be welltolerated, future studies will examine the effect of low-dose chemotherapeutic drug in
combination with higher doses of sigma 2 receptor ligands.
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Chapter 10: Conclusion and future directions
Cancer metastasis accounts for 90% cancer related deaths. EMT is the first step
in cancer metastases cascade and there are no therapeutic agents, which are known to
reverse EMT in aggressive cancer cells with a mesenchymal phenotype. ERK1/2 and
ERK5 pathways are known to induce EMT in several cancers; however, the effect of
inhibition of the ERK1/2 and ERK5 pathways on the reverse of EMT is not well-understood
in cancer. In our research, we utilized bioinformatics, drug discovery, and in vitro
approaches to develop strategies to reverse EMT and attenuate tumor forming and
metastatic abilities of breast and brain cancers.
Epigenetic pathways and crosstalk with the PI3K pathway may lower the efficacy
of ERK1/2 or ERK5 inhibitors on cell viability. Therefore, we designed combination
strategies to simultaneously target MAPK and PI3K pathways to target cell viability in
triple-negative breast cancer. Development of chemotherapeutic drug resistance is
another major problem associated with cancer. Emerging evidence suggests a role of
MAPK pathway in mediating chemo-resistance in cancer. Therefore, we developed
rational combination strategies to treat cancer cells with a combination of low-dose kinase
inhibitors and chemotherapeutic drugs and examined their effect on cell viability. The idea
is to utilize low doses of drugs in combination to achieve the same effect as high doses
of drugs alone to prevent collateral toxicity. In future, it would be worth assessing whether
treating cells with low-dose kinase inhibitors would prevent chemoresistance or treatment
of cells that have developed resistance to chemotherapeutic drugs with kinase inhibitors
could induce cell death.
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In conclusion, we have reported for the first time the effect MAPK pathway
inhibition on mesenchymal to epithelial transition, the reverse of EMT, nuclear localization
of ERK5 and ERK1/2, and crosstalk with the PI3K-AKT pathway in regulation of EMT and
chemotherapeutic sensitivity in breast cancer and glioblastoma models, which have a
mesenchymal phenotype.
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Appendix B Antibody inventory
Cancer research
Category

Kinase

EMT

Miscellaneous

Loading
control

Primary antibody

Antibody

Isotype

ERK5
pERK5
(Thr218/Tyr20)
ERK1/2 (p44/42)
pERK1/2 (phosphop44/42)
AKT (Ser 173)
p-AKT
E-Cadherin
N-Cadherin
Vimentin
ZO-1
Snail
Slug
TCF8/ZEB1
Claudin-1
pS6 (Ribosomal
protein)
Ki67 (cell proliferation
marker)
SOX2 (stem cell
biomarker)
α-tubulin
GAPDH

#Catalog
number
3372
3371

Application

R
R

Molecular
weight (kDa)
115
115

M
R

44, 42
44, 42

4695
9101

WB IP IHC
WB IP IF F

R
M
R
R
R
R
R
R
R
R
R

60
60
135
140
57
220
29
30
200
10
32

9272
4051
3195
13116
5741
5406
3879
9585
3396
13255

WB IP IHC
WB IP
WB IHC IF F
WB IP IHC IF
WB IHC IF F
WB IP
WB IP
WB IP
WB IP
WB IP IHC
WB IHC IF F

R

WB IP
WB

IHC

R

39

AB5603

WB IHC IF

M
R

52
37

3873
97166

WB IHC IF
WB

Secondary antibody
Reference
no.
92668021
92632210
A21429
A11001

Lot no.
C50618-03
C30701-01
1371057
1298479

Host
species
G
G
G
G

Reactivity
species
R
M
R
M
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Fluorophore/conjugate

Application

IRDye 680LT
IRDye 800CW
Alexa Fluor 555
Alexa Fluor 488

WB ICW
WB ICW
IF F IHC
IF F IHC

Appendix C Structures and data for novel quinazolines and thiophenes.
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Appendix D KEGG analysis of pathways upregulated in glioblastoma multiforme
Goal: To identify pathways that are upregulated in GBM.
Method: KEGG pathway analysis was performed to examine the pathways that are
upregulated in GBM tumor samples compared to non-tumor controls.
Result: MAPK signaling pathway and genes involved in regulation of the actin
cytoskeleton were among the top fifteen categories of significantly upregulated genes.
These findings suggest that MAPK pathway is an important target in GBM. The
signaling is also outlined below.
Tumor Brain (REMBRANDT study) - Madhavan - 550 - MAS5.0 - u133p2 public
disease~glioblastoma_multiforme,normal 256 of 550 samples, transform_log2
Grouping variable: disease
present calls >=1, selected genes (6968)
3298 combinations meet your criteria
2114 combinations did not meet T-test p<0.0001 as R and 1 as minimal # of
PresentCalls
Date of data procurement: 2-14-2021
Links
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R

K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K

Group

In_Set Total Percentage

All
A Axon_guidance
A Retrograde_endocannabinoid_signaling
A Spliceosome
A Glutamatergic_synapse
A Nicotine_addiction
A GABAergic_synapse
A Synaptic_vesicle_cycle
A Long_term_potentiation
A MAPK_signaling_pathway
A Circadian_entrainment
A Serotonergic_synapse
A Regulation_of_actin_cytoskeleton
A Pancreatic_cancer
A Lysosome
A N_Glycan_biosynthesis
A Amphetamine_addiction
A Colorectal_cancer
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3298 5412 60.9%
98 121 81.0%
74
89 83.1%
91 119 76.5%
82 106 77.4%
29
32 90.6%
61
77 79.2%
47
58 81.0%
49
61 80.3%
161 227 70.9%
63
83 75.9%
67
89 75.3%
133 189 70.4%
50
65 76.9%
81 111 73.0%
37
47 78.7%
46
60 76.7%
46
60 76.7%

pvalue
6.1e-06
1.8e-05
5.2e-04
5.3e-04
5.8e-04
1.0e-03
1.7e-03
1.9e-03
2.0e-03
5.2e-03
5.5e-03
7.9e-03
8.3e-03
9.4e-03
0.01
0.01
0.01

R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R

K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K
K

A Endometrial_cancer
A Oxytocin_signaling_pathway
A MicroRNAs_in_cancer
A Morphine_addiction
A Progesterone_mediated_oocyte_maturation
A Shigellosis
A Ribosome
A Vibrio_cholerae_infection
A DNA_replication
A ErbB_signaling_pathway
A Glycosaminoglycan_degradation
A Arginine_and_proline_metabolism
A Platelet_activation
A Mismatch_repair
A Lysine_degradation
A Cholinergic_synapse
A Focal_adhesion
A Dopaminergic_synapse
A Protein_processing_in_endoplasmic_reticulum
A Bladder_cancer
A Wnt_signaling_pathway

39
97
104
59
59
44
76
33
28
61
13
32
76
18
36
70
129
81
105
29
86

51 76.5%
138 70.3%
149 69.8%
81 72.8%
81 72.8%
59 74.6%
107 71.0%
43 76.7%
36 77.8%
85 71.8%
15 86.7%
42 76.2%
108 70.4%
22 81.8%
48 75.0%
99 70.7%
190 67.9%
116 69.8%
153 68.6%
38 76.3%
124 69.4%

0.02
0.02
0.03
0.03
0.03
0.03
0.03
0.03
0.04
0.04
0.04
0.04
0.04
0.04
0.05
0.05
0.05
0.05
0.05
0.05
0.05

Kyoto Encyclopedia of Genes and Genomes analysis of pathways regulating GBM
progression.
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Signaling pathways mediating tumorigenesis in GBM.
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Appendix E: Supporting Figures
Hypothesis: Novel diphenylamine compounds will induce MET in TAMR MCF-7 cells.
Method: TAMR MCF-7 cells were treated with diphenylamine compounds for 5 days.
The cells were fixed and stained with crystal violet dye and pictures were taken using
EVOS.
Result: Compounds reverse EMT in TAMR MCF-7 cells. The SAR obtained in MDAMB-231 cells was consistent across another model of breast cancer with a
mesenchymal phenotype.

Consistent with MDA-MB-231 cells, treatment with compounds 1, 2, and 9 induced
an MET in TAMR MCF-7 cells as examined by crystal violet staining of cells after
treatment with 1 uM compounds for 5 days.
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Goal: To examine the effect of diphenylamine analogs on AKT activation in MDA-MB231 cells.
Method: MDA-MB-231 cells were treated with diphenylamine compounds for 5 days.
Cell lysates were collected and examined for ERK1/2 and AKT activation via western
blotting.
Result: Compounds that inhibited ERK1/2 activation produced a compensatory
activation in the AKT pathway, consistent with previous studies.

Novel diphenylamine analogs and MEK1/2 or MEK5 inhibitors that inhibit MEK1/2
pathway produced a compensatory increase in AKT pathway.
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Hypothesis: Dual inhibition of ERK1/2 and ERK5 pathways will induce a MET in MDAMB-231 cells.
Method: MDA-MB-231 cells were treated with MEK1/2 inhibitor UO126 and ERK5
inhibitor AX15836 alone and in combination for 5 days. The cells were fixed and stained
with crystal violet dye and pictures were taken using EVOS. Cell lysates were collected
to examine E-cadherin protein expression. To determine kinase activation, MDA-MB231 cells were serum starved after 24 hours of plating. Inhibitors were added for 30
minutes followed by 15 minutes of EGF stimulation.
Result: UO126 alone and in combination with AX15826 induces a mesenchymal to
epithelial transition in MDA-MB-231 cells as determined by cell morphology and
increase in E-cadherin expression. Moreover, treatment with UO126 and AX15836
significantly decreased ERK5 activation by EGF. ERK5 inhibitor AX15836 also inhibited
ERK1/2, which was not anticipated and requires further validation.
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Compound 1 (SC-1-151) – like effects on cell morphology and E-cadherin protein
expression could be recapitulated by addition of combination of ERK1/2 inhibitor
UO-126 and ERK5 inhibitor AX15836.

UO+AX combination significantly decreased ERK5 activation by EGF. Moreover,
AX15836 significantly decreased ERK1/2 activation by EGF.

Hypothesis: Sequential addition of chemotherapeutic drugs after cells undergo MET
will be beneficial to enhance chemosensitivity in TNBC cells.
Method: MDA-MB-231 and BT-549 cells were treated with trametinib, XMD8-92, or
combination of Tra+XMD for 48 hours followed by chemotherapeutic drugs for 24 hours.
At 72 hours from initial treatment, MTT assay was performed to evaluate cell viability.
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Result: Our data indicate that prior treatment with kinase inhibitors does not sensitize
the cells (which are in the process of undergoing MET at this stage) to
chemotherapeutic drugs paclitaxel, doxorubicin, or carboplatin. Control (Con.) , [Tra] low
= 0.01, mid= 0.1, high=1 uM; [XMD] low = 0.1, mid= 1, high= 10 uM; [Tra], [XMD]: low =
0.01, 0.1), Med= 0.1, 1, High= 1, 10. This may be because of increase in drug efflux
transporters after treatment with kinase inhibitors.

Sequential chemotherapeutic drug treatment did not synergize with MAPK inhibitors in
MDA-MB-231 cells.
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Sequential chemotherapeutic drug treatment did not synergize with MAPK inhibitors in
BT-549 cells.
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